CTAD

Clinical Trials on Alzheimer's Disease

11th edition of Clinical Trials on Alzheimer's Disease

Preliminary Program

PALAU DE CONGRESSOS DE CATALUNYA
Barcelona, October 24-27, 2018

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14
Barcelona '15 / San Diego '16 / Boston '17

www.ctad-alzheimer.com

EADC
MONTPELLIER and TOULOUSE EADC Centers
European Alzheimer's Disease Consortium

Keck School of Medicine of USC
Alzheimer's Therapeutic Research Institute

JPAD

CTAD 2018

BARCELONA, SPAIN

Organizing and Scientific Committees ..... p. 3
Keynote Speakers ..... p. 4
Lifetime Achievement Award ..... p. 6
Program at a glance ..... p. 7
- Wednesday, October 24 ..... p. 9
- Thursday, October 25 ..... p. 10
- Friday, October 26 ..... p. 14
- Saturday, October 27 ..... p. 18

Poster presentations ..... p. 21
Theme 1. Clinical trials: Methodology ..... p. 22-24
Theme 2. Clinical trials: Results ..... p. 25-27
Theme 3. Clinical trials: Imaging ..... p. 28-29
Theme 4. Clinical trials: Biomarkers including plasma ..... p. 30-34
Theme 5. Clinical trials: Cognitive and functional endpoints ..... p. 35-38
Theme 6. Cognitive assessment and clinical trials ..... p. 39-42
Theme 7. Behavioral disorders and clinical trials ..... p. 43
Theme 8. Health economics and clinical trials ..... p. 44
Theme 9. Epidemiology and clinical trials ..... p. 45-46
Theme 10. Clinical Trials: Animal Models ..... p. 47
Theme 11. New therapies and clinical trials ..... p. 48-49
Our sponsors ..... p. 50
Registration / Accommodations ..... p. 51

design by laura frère - photo credit : istock photo - adobe stock

Clinical Trials on Alzheimer's Disease

CTAD Organizing Committee

Jacques Touchon MD, PhD
University
Hospital of Montpellier
France

Paul Aisen MD
Alzheimer's
Therapeutic Research Institute (ATRI)
University of Southern California (USC),
San Diego, USA

Bruno Vellas MD, PhD
University
Hospital of Toulouse
France

Mike Weiner MD
University of California
San Francisco (UCSF)
USA

CTAD Scientific Committee

Susan ABUSHAKRA (San Francisco)
Paul AISEN (San Diego)
Kaj BLENNOW (Molndal)
Merce BOADA (Barcelona)
Maria CARRILLO (Chicago)
Mony John DE LEON (New York)
Steven DEKOSKY (Miami)
Rachelle DOODY (Basel)
Bruno DUBOIS (Paris)
Howard FELDMAN (Vancouver)
Nick FOX (London)
Giovanni B. FRISONI (Brescia, Geneva)
Lutz FROELICH (Mannheim)
Serge GAUTHIER (Montreal)
Ezio GIACOBINI (Geneva)
Michael GRUNDMANN (San Diego)
Harald HAMPEL (Paris)
Takeshi IWATSUBO (Tokyo)
Ara KHACHATURIAN (Washington DC)
Zaven KHACHATURIAN (Washington DC)
Virginia LEE (Philadelphia)
Constantine G. LYKETSOS (Baltimore)
José Luis MOLINUEVO (Barcelona)
Jean-Marc ORGOGOZO (Bordeaux)
Ronald PETERSEN (Minnesota)
Craig W. RITCHIE (Edinburgh)
Augustin RUIZ (Barcelona)
Robert RISSMAN (San Diego)
Stephen SALLOWAY (Providence)
Rachel SCHINDLER (New York)
Philip SCHELTENS (Amsterdam)
Lon SCHNEIDER (Los Angeles)
Eric SIEMERS (Philadelphia)
Peter SNYDER (Rhode Island)
Reisa SPERLING (Boston)
Yaakov STERN (New York)
Jacques TOUCHON (Montpellier)
John TROJANOWSKI (Philadelphia)
Bruno VELLAS (Toulouse)
Michael W. WEINER (San Francisco)
Bengt WINBLAD (Stockholm)

Clinical Trials on Alzheimer's Disease

KEYNOTE SKEAKERS



«Blood biomarkers for AD clinical trials»

Randall Bateman, MD, PhD

Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA

Dr. Randall Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, is the PI of the Dominantly Inherited Alzheimer Network (DIAN) and DIAN Trials Unit which coordinates with pharmaceutical, regulatory, and patient advocacy groups for clinical trials in dominantly inherited Alzheimer's disease. Dr. Bateman's laboratory investigates the causes and future diagnosis and treatments of Alzheimer's disease utilizing a wide variety of assays and techniques. His lab measures the pathophysiology of Alzheimer's disease in humans utilizing amyloid-beta, apolipoprotein E, APP, and tau protein kinetics. His work has been supported by the NIH, foundations, and Pharma, and he has consulted for the FDA, NIH and Pharma. He has served as a co-investigator on multiple multi-site trials including ADNI and AD clinical trials. Dr. Bateman mentors junior faculty members, fellows, and students, all successful in their desired career trajectory. His contributions have been recognized with awards from the AlzForum Community, Alzheimer's Association (Zenith Award), Scientific American, the Glenn Award for Aging Research, and the MetLife Foundation.

«What have we learned from Aducanumab?»

Samantha Budd Haeberlein, PhD

Vice President of Alzheimer's Disease Discovery & Development, Biogen, Boston, USA

Samantha Budd Haeberlein, Ph.D., joined Biogen in February 2015 as Vice President of Alzheimer's Disease Discovery & Development. Dr Budd Haeberlein was previously Vice President of Translational Science at AstraZeneca where for fifteen years she led multi-disciplinary teams and functions across Research, Strategy, Translational Medicine and Clinical Development in the US, Canada and Sweden. Dr Budd Haeberlein has a BSc (Hons.) and PhD in Biochemistry from the University of Dundee in Scotland, and conducted research at Brigham & Women's Hospital Harvard Medical School in Boston, and at The Burnham Institute in San Diego.

«Anti-Tau Treatments: Potential, Challenges, and Progress»

Lennart Mucke, MD

Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA

Dr. Mucke is the founding director of the Gladstone Institute of Neurological Disease and holds joint appointments as the Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco. He trained at the Free University Berlin, the Georg-August University and the Max Planck Institute for Biophysical Chemistry in Göttingen, the Cleveland Clinic, the Massachusetts General Hospital and Harvard Medical School, and The Scripps Research Institute. Dr. Mucke's research focuses on mechanisms that result in functional deficits in Alzheimer's disease and other cognitive disorders. He has generated informative experimental models of these conditions and used them to identify novel strategies to prevent neurological decline. For his contributions, Dr. Mucke has received the Potamkin Prize, MetLife Foundation Award for Medical Research, Kalid Iqbal Lifetime Achievement Award, Zenith Award, American Pacesetter Award, MERIT Award, and an Award for Excellence in Direct Teaching and Mentoring. He is a member of the American Neurological Association and the Association of American Physicians, chairs the Senate of the German Center for Neurodegenerative Diseases, and has served on the Medical and Scientific Advisory Council of the Alzheimer's Association and on the National Advisory Council on Aging for the NIH.

Clinical Trials on Alzheimer's Disease

KEYNOTE SKEAKERS

«How BIG and GOOD Data are revolutionizing Neurodegenerative Disease Research»

Cristina Sampaio, MD, PhD

Chief Medical Officer, CHDI Foundation, Princeton, USA

Professor Cristina Sampaio joined CHDI Foundation as Chief Clinical Officer 6 years ago. She also holds the position of Professor of Clinical Pharmacology and Therapeutics at Faculdade de Medicina de Lisboa (currently on unpaid leave). At CHDI Professor Sampaio oversees an extensive portfolio of clinical projects ranging from experimental medicine, through biomarker and rating scale development to support drug development activities, to the development and maintenance of a global clinical research platform, Enroll-HD. Professor Sampaio spent 25 years of her career in academia where her primary research interests centered on clinical research methodology, clinical trial design, and related aspects of meta-research applied to movement disorders. Together with several colleagues she founded the Cochrane Movement Disorders Group (MovDisCRG) and became its coordinating editor in 1996, a position that she has shared with Professor Joao Costa from 2013 to 2018. She is now an Editor of The MovDisCRG. Professor Sampaio published 170 peer review papers and book chapters. From 1998 to 2011, Professor Sampaio was a member of the Committee on Human Medicinal Products and the Scientific Advice Working Party at the European Medicines Agency. During this period, she had a very active role in the development of the standards of regulatory science for CNS medicinal products in the European Union. She was rapporteur, coordinator, or assessor of over 400 medicinal products files submitted to EMA for licensing or scientific advice and she coordinated the first clinical biomarker qualification in the EU. Professor Sampaio obtained her MD in 1986 and her PhD in clinical pharmacology in 1997 from the University of Lisbon. She is a board-certified clinical pharmacologist, receiving neurological training in the Neurology department of Hospital St Maria in Lisbon. She was a staff member of the Movement Disorders Clinic from 1988 to 2011, President of the Portuguese Movement Disorders Society 2008-2012, and Chair of the Evidence-based Medicine Committee of the International Parkinson and Movement Disorder Society 2010-2014.

«Combination therapy in AD»

Daniel M. Skovronsky, MD, PhD

Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

Dr. Daniel M. Skovronsky, serves as Senior Vice President of Clinical and Product Development at Eli Lilly and Company. Dr. Skovronsky is responsible for developing the Lilly pipeline of molecules. He was the Founder, Chief Executive Officer and President at Avid Radiopharmaceuticals Inc. Dr. Skovronsky founded Avid Radiopharmaceuticals in 2004. Prior to establishing the firm, he served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky served as Vice President of Radiopharmaceutical Development at Theracor Pharmaceuticals. He served as a Member of Advisory Board of Safeguard Scientifics, Inc., until October 21, 2015 and previously served as a Member of its Life Sciences Advisory Board. Dr. Skovronsky serves as a Director of Avid Radiopharmaceuticals, Inc. He has more than 20 peer-reviewed publications and two NIH-funded grants on Alzheimer's disease research. He is the recipient of numerous scientific and business awards and was named by the Philadelphia Business Journal as one of their Forty under Forty business leaders in the region. Dr. Skovronsky received the Ernst & Young Entrepreneur Of The Year 2009 Award in the Emerging Company category, which recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. He trained as a resident in Pathology and completed a Fellowship in Neuropathology at the Hospital of the University of Pennsylvania. Dr. Skovronsky received his MD and PhD from the University of Pennsylvania and did BS degree in Molecular Biochemistry at Yale University.

Clinical Trials on Alzheimer's Disease

2018 Recipient of the CTAD Lifetime Achievement Award

Rachelle Doody MD, PhD

Rachelle Doody MD, PhD is the Global Head of Neurodegeneration in Pharma Development, Neuroscience for Roche Pharmaceutical Company and it US entity, Genentech. Prior to joining Genentech/Roche in September, 2016, Dr. Doody was the Effie Marie Cain Chair in Alzheimer's Disease Research at Baylor College of Medicine, in Houston, Texas where she founded and directed the Alzheimer's Disease and Memory Disorders Center over a period of 27 years.

While at Baylor, she published over 200 original research articles, served on the steering committees for the National Institutes of Health-funded Alzheimer's Disease Cooperative Study (ADCS) and Alzheimer's Disease Neuroimaging Initiative (ADNI), and the executive committee for the Alzheimer's Therapeutic Research Institute (ATRI).

In her role as a practicing Neurologist, Dr. Doody was elected to Best Doctors in America from 1996-2016. She has received many awards from professional and civic groups, including Distinguished Alumni Award from Rice University in 2009 and Distinguished Faculty Award from Baylor College of Medicine in 2011.

CTAD 2018

PROGRAM AT GLANCE

Wednesday, October 24

4.00 - 4.30 p.m.	Opening Ceremony and CTAD Lifetime Achievement Award
4.30 - 5.00 p.m.	Keynote 1 - Blood biomarkers for AD clinical trials
5.00 - 5.50 p.m.	Symposium 1 - APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer's disease
5.50 - 6.40 p.m.	Emerging Results From Other BACE Inhibitor Trials Discussion of BACEi Trial Findings: Challenges and Opportunities
6.40 - 7.00 p.m.	Late breaking oral communication

Thursday, October 25

8.30 - 10.00 a.m.	Oral communications
10.00 - 10.30 a.m.	Coffee break and poster session
10.30 - 11.30 a.m.	Symposium 2 - Is BACE1 a suitable drug target for prevention and treatment of Alzheimer's disease?
11.30 - 12.30 p.m.	Oral communications
12.30 - 1.30 p.m.	Lunch and poster session
1.30 - 2.00 p.m.	Keynote 2 - What have we learned from Aducanumab?
2.00 - 2.30 p.m.	Late breaking oral communications
2.30 - 3.30 p.m.	Symposium 3 - Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD
3.30 - 4.30 p.m.	Oral communications
4.30 - 5.00 p.m.	Coffee break and poster session
5.00 - 6.00 p.m.	Symposium 4 - Aβ blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer's disease.

Friday, October 26

8.30 - 10.00 a.m.	Oral communications
10.00 - 10.30 a.m.	Coffee break and poster session
10.30 - 11.00 a.m.	Keynote 3 - Anti-Tau treatments: Potential, challenges, and progress
11.00 - 11.30 p.m.	Late Breaking communications
11.30 - 12.30 p.m.	Symposium 5 - Towards the Development of a Complete Solution for Patients with Alzheimer's Disease (AD)
12.30 - 1.30 p.m.	Lunch and poster session
1.30 - 2.45 p.m.	Oral communications
2.45 - 4.00 p.m.	Late Breaking communications
4.00 - 4.30 p.m.	Coffee break and poster session
4.30 - 5.00 p.m.	Keynote 4 - Combination therapy in AD
5.00 - 6.00 p.m.	Symposium 6 - Endpoints for early Alzheimer's disease clinical trials: Interpretation and application of the draft FDA guidance

Saturday, October 27

8.30 - 9.15 a.m.	Presentation and panel discussion: AMBAR (Alzheimer's Management By Albumin Replacement) Phase IIb/III Results
9.15 - 9.45 a.m.	Keynote 5 - How BIG and GOOD Data are revolutionizing neurodegenerative disease research
9.45 - 10.15 a.m.	Coffee break and poster session
10.15 - 11.15 a.m.	Oral communications
11.15 - 12.15 p.m.	Symposium 7 - Disclosure of Alzheimer's risk biomarkers to cognitively normal older adults
12.15 - 1.15 p.m.	Lunch and poster session
1.15 - 3.45 p.m.	Oral communications
3.45 p.m.	End of conference

Wednesday, October 24

4.00 - 4.30 p.m.

Opening Ceremony and CTAD Lifetime Achievement Award

Jacques Touchon, Paul Aisen, Bruno Vellas, Mike Weiner, Merce Boada, Jose Luis Molinuevo. The recipient of this year's CTAD Lifetime Achievement Award is Rachelle S. Doody M.D., Ph.D. Global Head of Neurodegeneration, Roche, Basel - Switzerland for her work dedicated to academic and industrial research in AD clinical trials

4.30 - 5.00 p.m.

Keynote 1

Blood biomarkers for AD clinical trials

Randall Bateman, MD, PhD - Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA

5.00 - 5.50 p.m.

Symposium 1

APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer's disease

Symposium moderator: Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA

Communication 1: Results from the APECS trial

Michael F. Egan, MD[1], Tiffini Voss, MD[1], Yuki Mukai, MD[1], James Kost, PhD[1], Paul S Aisen, MD[2], Jeffrey L. Cummings, MD, ScD[3], Pierre N. Tariot, MD[4], Bruno Vellas, MD, PhD[5], Christopher H. van Dyck, MD[6], Ying Zhang, PhD[1], Wen Li, PhD[1], Christine Furtek, BS[1], Erin Mahoney, BA[1], Lyn Harper Mozley, PhD[1], Yi Mo, PhD[1], Cyrille Sur, PhD[1], David Michelson, MD[1]

[1]Merck & Co., Inc., Kenilworth, NJ, USA [2]University of Southern California, San Diego, CA, USA [3]Cleveland Clinic, Las Vegas, NV, USA [4]Banner Alzheimer's Institute, Phoenix, AZ, USA [5]Gerontopole, INSERM U 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France [6]Yale University School of Medicine, New Haven, CT, USA

Communication 2: Panel discussion

Paul S. Aisen, MD[1], Maria C. Carrillo, PhD[2], Pierre N. Tariot, MD[3], Bruno Vellas, MD, PhD[4]

[1]University of Southern California, San Diego, CA, USA [2]The Alzheimer Association, Chicago, IL, USA [3]Banner Alzheimer's Institute, Phoenix, AZ, USA [4]Gerontopole, INSERM U 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France

5.50 - 6.40 p.m.

Emerging Results From Other BACE Inhibitor Trials

Discussion of BACEi Trial Findings: Challenges and Opportunities

CoChairs: Reisa Sperling, MD, Brigham & Women's Hospital, Maria C. Carrillo, PhD, Alzheimer's Association

Presentation 1: Preliminary analyses of data from an ongoing trial of atabecestat in preclinical Alzheimer's disease. Gary Romano, MD, PhD Janssen R&D, USA

Presentation 2: LB1 - Results from the phase 2 NAVIGATE-AD clinical trial evaluating LY3202626 BACE inhibitor in patients with mild Alzheimer's disease dementia.

Albert C Lo[1], Cynthia Duggan Evans[1], Michele Mancini[1], Qun Lin, Hong Wang[1], Peng Liu[1], Sergey Shcherbinin[1], Ming Lu[2], Arnaud Charil[1], Brian A Willis[1], Michael Irizarry[3]

[1]Eli Lilly and Company, Indianapolis, IN, USA, [2]Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, USA, [3]Eli Lilly and Company, Indianapolis IN, USA; now at Eisai Inc, Woodcliff Lake, NJ

Panel discussion: Reisa Sperling, MD, Brigham & Women's Hospital, Maria C. Carrillo, PhD, Alzheimer's Association, Mark Mintun, MD, Eli Lilly & Co., Michael Egan, MD, Merck & Co., Gary Romano, MD, PhD Janssen R&D, Ana Graf, MD, Novartis & Amgen, Inc., Johan Luthman, MD, Eisai Co., Ltd., John Sims, MD, Lilly/AZ Alliance

6.40 - 7.00 p.m.

Late Breaking Oral communication

6.40 - 7.00 p.m.

LB2 - TOMMORROW: a trial to delay the onset of MCI due to AD and qualify a genetic biomarker algorithm: topline results

Robert Alexander, MD[1], Daniel K. Burns, PhD[2], Kathleen A. Welsh-Bohmer, PhD[3], Carl Chiang, PhD[2], Meredith Culp, BS[4], Janet O'Neil, MBA[4], Brenda L. Plassman, PhD[3], Craig Metz, PhD[2], Deborah Yarbrough, MS, MBA[4], Jingtao Wu, PhD[1], Rebecca Evans, MD[1], Kumar Budur, MD[4], Stephen K. Brannan, MD[4], Ann M. Saunders, PhD[2], Emiliangelo Ratti, PhD[1]; for the TOMMORROW Study Investigators

[1]Takeda Development Center Americas, Inc., Cambridge, MA, USA, [2]Zinfandel Pharmaceuticals, Inc., Durham, NC, USA, [3]Duke University Bryan ADRC, Durham, NC, USA, [4]Takeda Development Center Americas, Inc., Deerfield, IL, USA

Thursday, October 25

8.30 - 10.00 a.m.

Oral communications

8.30 - 8.45 a.m.

OC1 - Phase 2a trial of AZD0530 evaluating 18F-FDG PET, safety, and tolerability in mild Alzheimer's dementia

Christopher H. van Dyck, MD[1], Haakon B. Nygaard, MD, PhD[2], Kewei Chen, PhD[3], Michael C. Donohue, PhD[4], Rema Raman, PhD[4], Robert A. Rissman, PhD[4,5], James B. Brewer, MD, PhD[5], Robert A. Koeppe, PhD[6], Tiffany W. Chow, MD[4], Michael S. Rafii, MD[4], R. Scott Turner, MD, PhD[7], Jeffrey A. Kaye, MD[8], Seth A. Gale, MD[9], Eric M. Reiman, MD[3], Paul S. Aisen, MD[4], Stephen M. Strittmatter, MD, PhD[1]

[1]Yale University School of Medicine, New Haven, USA [2]The University of British Columbia, Vancouver, Canada [3]Banner Alzheimer's Institute, Phoenix, USA [4]Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, USA [5]University of California San Diego, La Jolla, USA [6]University of Michigan, Ann Arbor, USA [7]Georgetown University, Washington, DC, USA [8]Oregon Health & Science University, Portland, USA [9]Harvard Medical School, Boston, USA

8.45 - 9.00 a.m.

OC2 - Primary results from a phase II/III trial of intranasal insulin: A novel multi-target molecule and delivery mode for AD therapeutics

Suzanne Craft, PhD[1], Rema Raman, PhD[2], Tiffany Chow, MD[2], Michael S Rafii, MD[2], Robert A. Rissman, PhD[3], James B. Brewer, MD[3], Michael Donohue, PhD[2], Chung-Kai Sun,MS[2], Kelly Harless[2], Devon Gessert[2], Paul S. Aisen, MD[2]

[1]Wake Forest School of Medicine, Winston-Salem, USA, [2]University of Southern California, Los Angeles, USA, [3]University of California, San Diego, USA

9.00 - 9.15 a.m.

OC3 - Phase3 clinical trial for a novel and multi-targeted oligosaccharide in patients with mild-moderate AD in China

Shifu Xiao, MD[1], Zhenxin Zhang, MD[2], Meiyu Geng, PhD[3], GV-971 Study Group

[1]Department of Gerontology, Shanghai Mental Health Center, Shanghai Jiao Tong University, Shanghai, China [2]Peking Union Medical College Hospital, Beijing, China [3]State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

9.15 - 9.30 a.m

OC4 - Active Anti-amyloid Immunotherapy with UB-311 Vaccine: Design, baseline data and study update of a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study

Ajay Verma, Hui Jing Yu, Hui-Chen Chen, and Chang Yi Wang on behalf of the UB-311 Phase IIa Study Team

United Neuroscience, Inc. Hauppauge, NY, USA

9.30 - 9.45 a.m.

OC5 - Elenbecestat in MCI-to-moderate Alzheimer's disease: Safety and effectiveness as measured by amyloid PET and the ADCOMS clinical endpoints

Shau Yu Lynch, PhD[1], June Kaplow, PhD[1], Jim Zhao, MS, MM[1], Shobha Dhadda, PhD[1], Johan Luthman, PhD, DDS[1], Bruce Albala, PhD[1]

[1]Eisai Inc., Woodcliff Lake, NJ, USA

9.45 - 10.00 a.m.

OC6 - ALLOPREGNANOLONE regenerative therapeutic for mild cognitive impairment and mild Alzheimer's disease: Phase 1b/2a outcomes update

Roberta D. Brinton, PhD[1], Gerson D. Hernandez, MD, MPH[1], Naoko Kono, MPH[2], Claudia M. Lopez, BS[1], Christine Solinsky, PhD[3], Kathleen Rodgers, PhD[1], Jin Gahm, PhD[4], Dogu Aydogan, PhD[4], Yonggang Shi, PhD[4], Sonia Pawluczyk, MD[5], Meng Law, MD[6], Wendy Mack, PhD[2], Lon Schneider, MD, MS[5]

[1]Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA [2]Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA [3]School of Pharmacy, University of Southern California, Los Angeles, CA, USA. [4]USC Institute for Neuroimaging and Informatics, University of Southern California, Los Angeles, CA, USA. [5]Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA [6]Department of Radiology, University of Southern California, Los Angeles, CA, USA

10.00 - 10.30 a.m.

Coffee break and poster session

Thursday, October 25

10.30 - 11.30 a.m.

Symposium 2

Is BACE1 a suitable drug target for prevention and treatment of Alzheimer's disease?

Symposium moderator: Randall J. Bateman, MD, Department of Neurology, St. Louis, MO, USA

Communication 1: Physiological substrates of BACE1: safety issues or biomarkers ?
Stefan F. Lichtenthaler, PhD German Center for Neurodegenerative Diseases (DZNE) and Technical University of Munich (TUM), Germany

Communication 2: Secretase inhibitors in AD prevention trials: optimizing success and mitigating risk.
Eric McDade, DO, Department of Neurology, St. Louis, MO, USA

Communication 3: Considerations and lessons learned for the design and implementation of AD clinical trials evaluating BACE inhibitors.
Bruce Albala, PhD and Johan Luthman, PhD; Eisai, Inc., NJ, USA

11.30 - 12.30 p.m.

Oral communications

11.30 - 11.45 a.m.

OC7 - Impact of Amyloid PET on the management of cognitively impaired patients: Results from the IDEAS study
Gil D. Rabinovici,[1] Constantine Gatsonis,[2] Charles Apgar,[3] Kiran Chaudhary,[1] Ilana Gareen,[2] Lucy Hanna,[2] James Hendrix,[4], Bruce E. Hillner,[5] Cynthia Olson,[3] Orit Lesman-Segev,[1] Justin Romanoff,[2] Barry A. Siegel,[6] Rachel A. Whitmer,[7] Maria C. Carrillo,[4] on behalf of the IDEAS investigators.

[1]Department of Neurology, University of California San Francisco, [2]Center for Statistical Sciences, Brown University, [3]American College of Radiology, [4]Alzheimer's Association, [5]Department of Medicine, Virginia Commonwealth University, [6]Department of Radiology, Washington University, [7]Division of Research, Kaiser Permanente

11.45 - 12.00 p.m.

OC8 - Safety and efficacy of estrogen receptor-β targeted PhytoSERM formulation for cognitive complaints and vasomotor symptoms: Phase 1b/2a trial outcomes
Lon S. Schneider, MD[1], Gerson Hernandez MD MPH[2], Liqin Zhao PhD[3], Sonia Pawluczyk MD,[1] Wendy J. Mack, PhD[1], Roberta D. Brinton PhD[2]

[1]Keck School of Medicine of the University of Southern California, Los Angeles, USA, [2]University of Arizona, Center for Innovation in Brain Science, Tucson, USA, [3]University of Kansas, USA

12.00 - 12.15 p.m.

OC9 - Interim safety and efficacy results of pilot trial of GM-CSF/sargramostim in mild to moderate AD
Huntington Potter, PhD Jonathan H. Woodcock, Timothy Boyd, Stefan H. Sillau, Thomas Borges, Brianne M. Bettcher, Joseph Daniels

Rocky Mountain Alzheimer's Disease Center, Department of Neurology University of Colorado School of Medicine

12.15 - 12.30 p.m.

OC10 - Untangled – peptide-based inhibitors of tau aggregation as a potential treatment for Alzheimer's disease
David Allsop PhD[1,2], Anthony Aggidis MSc[1], Nigel Fullwood PhD[1], Mark Taylor PhD[1,2], Penny Foulds PhD[1,2], Shoona Vincent PhD[2], Mark Dale MD[2]

[1]Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK, [2]Peptide Innovations Limited, Affiliated Company of MAC Research, Blackpool, UK

12.30 - 1.30 p.m.

Lunch and poster session

1.30 - 2.00 p.m.

Keynote 2

What have we learned from Aducanumab?

Samantha Budd Haeberlein, PhD - Vice President of Alzheimer's Disease Discovery & Development, Biogen, Boston, USA

Thursday, October 25

2.00 - 2.30 p.m.

Late Breaking Oral communications

2.00 - 2.15 p.m.

LB3 - Lu AF20513, an active immunotherapy against amyloid beta, in development for patients in early stages of Alzheimer's disease

Bjørn Sperling, MD[1], Lars Østergaard Pedersen, PhD[1], Neli Boneva, MD[1], Dorthe Daugaard, MD[1], Yudong Zhao, PhD[1]

[1]H. Lundbeck A/S, Valby, Denmark

2.15 - 2.30 p.m.

LB4 - Predictors of [18F]flortaucipir (tau) load in Alzheimer's disease and other neurodegenerative disorders

Oskar Hansson, MD, PhD[1,2], Gil D. Rabinovici MD, PhD[3], Chul H. Lyoo, MD, PhD[4] & Rik Ossenkoppele, PhD[1,5]

[1]Lund University, Clinical Memory Research Unit, Lund, Sweden, [2]Memory Clinic, Skåne University Hospital, Malmö, Sweden, [3]Department of Neurology, University of California San Francisco, San Francisco, USA, Memory and Aging Center, [4]Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, [5]VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands

2.30 - 3.30 p.m.

Symposium 3

Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD

Eisai Inc, Woodcliff Lake, NJ, USA

3.30 - 4.30 p.m.

Oral communications

3.30 - 3.45 p.m.

OC11 - Safety and efficacy of lemborexant for sleep-wake regulation in patients with irregular sleep wake rhythm disorder and Alzheimer's disease dementia

Margaret Moline, PhD[1], Mohammad Bsharat, PhD[1], Manuel Kemethofer, MSc[2], Gleb Filippov, MD, PhD[1], Naoki Kubota, MPharm[3], Patricia Murphy, PhD[1]

[1]Eisai, Inc., Woodcliff Lake, USA, [2]The Siesta Group, Vienna, Austria, [3]Eisai Co. Ltd., Tokyo, Japan

3.45 - 4.00 p.m.

OC12 - Tau PET imaging as a screening tool for clinical trials of disease modifying therapies

Adam S Fleisher[2], Michael J Pontecorvo[2], Michael D Devous[2], Ming Lu[2], Sergey Shcherbinin[1], Anupa K Arora[2], Mark A Mintun[1,2].

[1]Eli Lilly & Co, Indianapolis, IN, USA, [2]Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

4.00- 4.15 p.m.

OC13 - BACE inhibition by verubecestat produces a rapid, non-progressive reduction in brain and hippocampal volume in Alzheimer's disease

Cyrille Sur, PhD[1], James Kost, PhD[1], David Scott, PhD[2], Katarzyna Adamczuk, PhD[2], Nick C Fox, PhD[3], Jeffrey Cummings, MD, ScD[4], Pierre Tariot, MD[5], Paul Aisen, MD[6], Bruno Vellas, MD, PhD[7], Tiffini Voss, MD[1], Yuki Mukai, MD[1], David Michelson, MD[1], Michael Egan, MD[1]

[1]Merck & Co., Inc., Kenilworth, NJ, USA, [2]Bioclinica, Newark, CA, USA, [3]University College London, London, UK, [4]Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, [5]BannerAlzheimer's Institute, Phoenix, AZ, USA, [6]University of California San Diego, San Diego, CA, USA, [7]Gerontopole, Toulouse University Hospital, Toulouse, France

4.15- 4.30 p.m.

OC14 - Distinct Tau PET Patterns in Atrophy-Defined Subtypes of Alzheimer's disease

Rik Ossenkoppele, Ph.D.[1,2], Gil D. Rabinovici, M.D.[3], Chul H. Lyoo, M.D., Ph.D.[4] & Oskar Hansson, M.D., Ph.D.[1,5]

[1]Lund University, Clinical Memory Research Unit, Lund, Sweden, [2]VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands, [3]Department of Neurology, University of California San Francisco, San Francisco, USA, Memory and Aging Center, [4]Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, [5]Memory Clinic, Skåne University Hospital, Malmö, Sweden.

4.30 - 5.00 p.m.

Coffee break and poster session

Thursday, October 25

5.00 - 6.00 p.m.

Symposium 4

Aβ blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer's disease.

Moderator : Pedro Pesini PhD. Araclon Biotech-Grifols, Spain.

Communication 1: Developing Aβ blood based test into pre- screening tools for clinical trials in early stages of AD
Victor L. Villemagne, M.D. Dept of Molecular Imaging & Therapy, Austin Health, Dept of Medicine, The University of Melbourne.

Communication 2: Plasma ratio of total Aβ42 to total Aβ40 in amnestic MCI patients is associated with FDG-PET, amyloid- PET, CSF and the risk of progression to AD dementia.
Anne Fagan PhD, Washington University, Saint Louis, Missouri.

Communication 3: Total Aβ42 to total Aβ40 as a biomarker of cortical amyloid burden in subjects with subjective memory complains.
Agustín Ruiz MD PhD. Research Director, Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades. Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Friday, October 26

8.30 - 10.00 a.m.

Oral communications

8.30 - 8.45 a.m.

OC15 - Cocoa supplement and multivitamin outcomes study of cognitive function (cosmos-mind): design of a large randomized clinical trial

Laura D. Baker, PhD[1], Mark A. Espeland, PhD[1], Stephen R. Rapp, PhD[1], Sally A, Shumaker, PhD[1], Sarah A, Gaussoin, MSI, Howard D. Sesso, ScD[2], JoAnn E. Manson, MD, DrPH[2]

[1]Wake Forest School of Medicine, Winston-Salem, USA, [2]Brigham and Women's Hospital, Harvard Medical School, Boston, USA

8.45 - 9.00 a.m.

OC16 - Rationale and design of a prospective, randomized, double-blind, dose-comparison safety and tolerability study of GRF6019 in mild-to-moderate Alzheimer's disease

Jonas Hannestad, MD PhD[1], Ian Gallager, PhD[1], Katie Koborsi, MS[1], S. Sakura Minami, PhD[1], Darby Stephens, MBA[1], Viktoria Kheifets, PhD[1], Steven Braithwaite, PhD[1]

[1]Alkahest, Inc., San Carlos, USA

9.00 - 9.15 a.m.

OC17 - Machine learning algorithm helps identify non-diagnosed prodromal Alzheimer's disease patients in general population

Olga Uspenskaya-Cadoz[1], Chaitanya Alamuri[2], Sam Khinda[3], Yuliya Nigmatullina[2], Carolina Rubel[3], Lanhui Wang[2], Mengting Yang[2], Tao Cao[2], Nikhil Kayal[2]

[1]IQVIA CNS Center of Excellence, [2]IQVIA Analytics Center of Excellence, [3]IQVIA Project Leadership

9.15 - 9.30 a.m.

OC18 - ABBV-8E12, a humanized anti-tau monoclonal antibody, for treating early Alzheimer's disease: Updated design and baseline characteristics of phase 2 study

Hana Florian, MD1, Steven E. Arnold, MD[2], Randall J. Bateman, MD[3], Joel B. Braunstein, MD, MBA[4], Kumar Budur, MD[1], Diana R. Kerwin, MD[5], Holly Soares, PhD[1], Deli Wang, PhD[1], David M. Holtzman, MD[3]

[1]AbbVie, Inc., North Chicago, IL, USA, [2]Massachusetts General Hospital, Boston, MA, USA, [3]Washington University, St. Louis, MO, USA [4]C$_2$N Diagnostics LLC, St. Louis, MO, USA, [5]Texas Health Presbyterian Hospital, Dallas, TX, USA

9.30 - 9.45 a.m.

OC19 - Assessment of clinical meaningfulness of endpoints in the Generation Program by the Insights to Model Alzheimer's Progression in real life (IMAP) study

A. Graf[1], V. Risson[1], S. Tzivelekis[2], A. Gustavsson[3], V. Bezlyak[1], A. Caputol, P.N. Tariot[4], J.B. Langbaum[4], C. Lopez Lopez[1] V. Viglietta[2]

[1]Novartis Pharma AG, [2]Amgen, Inc., [3]Quantify Research, [4]Banner Alzheimer's Institute

9.45 - 10.00 a.m.

OC20 - Characterizing clinical severity among biomarker positive individuals: Applying the 2018 NIA-AA research criteria for Alzheimer's disease to four large study cohorts.

Roos J. Jutten, MSc[1], Rebecca E. Amariglio, PhD[2,3], Gad A. Marshall, MD, PhD[2,3], Dorene M. Rentz, PhD[2,3], Wiesje M. Van der Flier, PhD[1], Philip Scheltens, MD, PhD[1], Keith A. Johnson[2,4], Reisa A. Sperling, MD[2,3], PhD, Sietske A.M. Sikkes, PhD[1,3], Kathryn V. Papp, PhD[2,3]

[1]Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, [2]Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA, [3]Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA, [4]Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA

10.00 - 10.30 a.m.

Coffee break and poster session

10.30 - 11.00 a.m.

Keynote 3

Anti-Tau treatments: Potential, challenges, and progress

Lennart Mucke, MD Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA

Friday, October 26

11.00 - 11.30 p.m.

Late Breaking communications

11.00 - 11.30 a.m.

LB5 - 18F-AV-1451-A16: A clinico-pathological study of the correspondence between flortaucipir PET imaging and post-mortem assessment of tau pathology

Mark A. Mintun[1,2], Adam S. Fleisher[2], Michael D. Devous[2], Ming Lu[2], Anupa K. Arora[2], Thomas G. Beach[3], Thomas J. Montine[4], Michael J. Pontecorvo[2]

[1]Eli Lilly and Company, Indianapolis, IN, USA, [2]Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA, [3]Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, AZ, USA, [4]Department of Pathology, Stanford University, Stanford, CA, USA

11.30 - 12.30 p.m.

Symposium 5

Towards the Development of a Complete Solution for Patients with Alzheimer's Disease (AD)

Moderator : Rachelle Doody, MD, PhD[1,2]
[1]Genentech, Inc., South San Francisco, CA, USA, [2]F. Hoffmann-La Roche Ltd, Basel, Switzerland

Communication 1: Self-detection of cognitive problems: benefits and challenges of online and digital tools
Mary Sano, PhD[1,2]
[1]Director, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, [2]Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Communication 2: Enhancing earlier and more reliable diagnosis of AD through the use of emerging biomarkers
Christopher van Dyck, MD[1–4]
[1]Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA, [2]Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA, [3]Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA, [4]Department of Neurology, Yale University School of Medicine, New Haven, CT, USA

Communication 3: Moving towards combination therapies for disease modification in AD
Dennis J. Selkoe, MD[1,2]
[1]Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA, [2]Harvard Medical School, Boston, MA, USA

12.30 - 1.30 p.m.

Lunch and poster session

1.30 - 2.45 p.m.

Oral communications

1.30 - 1.45 p.m.

OC21 - Extension and validation of an amyloid staging model: Associations with clinical measures

Lyduine Collij, MSc,[1] Fiona Heeman, MSc,[1] Gemma Salvadó Blasco, MSc,[2] Elles Konijnenberg, MD, MSc,[3] Anouk den Braber, PhD,[4] Maqsood Yaqub, PhD,[1] Pieter Jelle Visser, MD, PhD,[3] Alle Meije Wink, Ir, PhD,[1] Philip Scheltens, MD, PhD,[3] Ronald Boellaard, PhD,[1] Bart N.M. van Berckel, MD, PhD,[1] Juan Domingo Gispert López, PhD,[2] Mark Schmidt, MD, PhD,[5] Frederik Barkhof, MD, PhD,[1,6] Isadora Lopes Alves, PhD.[1]

[1]Dept. of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, [2]BarcelonaBeta Brain Research Center, Barcelona, Spain, [3]Alzheimer Center and Dept. of Neurology, VU University Medical Center, Amsterdam, The Netherlands, [4]Dept. of Biological Psychology, VU University Amsterdam, The Netherlands, [5]Janssen Pharmaceutica, Beerse, Belgium, [6]Institute of Neurology and Healthcare Engineering, University College London, London, United Kingdom.

1.45 - 2.00 p.m.

OC22 - Twenty-four–month amyloid PET results of the gantenerumab high-dose SCarlet and Marguerite RoAD open- label extension studies

Gregory Klein, PhD[1], Paul Delmar, PhD[2], Carsten Hofmann, PhD[1], Danielle Abi-Saab, PsyD[2], Mirjana Andjelkovic, PhD[2], Smiljana Ristic, MD[2], Nicola Voyle, PhD[3], Jacob Hesterman, PhD[4], John Seibyl[4], Ken Marek[4], Ferenc Martenyi, MD[2], Monika Baudler, PhD[2], Paulo Fontoura, MD, PhD[2], Rachelle Doody, MD, PhD[2]

[1]Roche Pharma Research and Early Development, Basel, Switzerland, [2]Roche / Genentech Product Development, Neuroscience, Basel, Switzerland, [3]Roche Products Ltd, Welwyn Garden City, UK, [4]InviCRO, LLC, Boston, MA, US

Friday, October 26

2.00 - 2.15 p.m.

OC23 - Multi-domain interventions to prevent dementia: from FINGER to World-Wide FINGERS

Miia Kivipelto[1,2,3], On behalf of the World-Wide FINGERS network

[1]Karolinska Institutet, Department of Clinical Geriatrics, Center for Alzheimer Research, Stockholm, Sweden,[2]University of Eastern Finland, Institute of Clinical Medicine/Neurology, Kuopio, Finland, [3]Imperial College London, NEA, School of Public Health, UK

2.15 - 2.30 p.m.

OC24 - Identifying risk of cognitive decline in Mild Cognitive Impairment for population enrichment of clinical trials

Christian Dansereau[1,2], PhD, Maor Zaltzhendler[1], MEng, Angela Tam[2,3], MSc, Pedro Rosa-Neto[3], MD, PhD, Serge Gauthier[3], MD, Pierre Bellec[2,4], PhD

[1]Perceiv Research Inc., Montreal, CAN, [2]Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, CAN, [3]Douglas Mental Health University Institute, McGill University, CAN, [4]Department of Computer Science and Operations Research, University of Montreal, CAN

2.30 - 2.45 p.m.

OC25 - Study update on XanADu: Phase II study of XanamemTM in subjects with mild dementia due to Alzheimer's disease

Craig Ritchie, MD, PhD, Centre for Dementia Prevention, University of Edinburgh, UK

2.45 - 4.00 p.m.

Late Breaking communications

2.45 - 3.00 p.m.

LB6 - Age and ApoE genotype-specific population frequencies of cerebral β-amyloidosis and hippocampal atrophy among cognitively normal individuals in CHARIOT-PRO

Hany Rofael, MD, PhD[1], Gerald Novak MD[1], Luc Bracoud MSc[2], Nandini Raghavan PhD[1], Ziad Saad PhD[3], S Einstein MS[1], Robert Brashear[1], David Scott PhD[4], Joel Schaerer PhD[2], Celeste de Jager PhD[5], Chi Udeh-Momoh, PhD[5], the Alzheimer's Disease Neuroimaging Initiative (ADNI), and Lefkos Middleton MD[5]

3.00 - 3.15 p.m.

LB7 - Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in participants with mild Alzheimer's disease

Marwan Sabbagh, MD[1], Imogene Dunn, PhD[2], Ann Gooch, PhD[2], Tom Soeder, MS[3], Karl Kieburtz, MD, MPH[4], Carmen Valcarce, PhD[2], Larry D Altstiel, MD, PhD[2]*, Aaron H Burstein, PharmD[2]

[1]Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, [2]vTv Therapeutics LLC, High Point, NC, USA, [3]Cato Research LTD, Durham, NC, USA, [4]Clintrex LLC, Longboat Key, FL, USA

3.15 - 3.30 p.m.

LB8 - Aducanumab titration dosing regimen: 36-month analyses from PRIME, a Phase 1b study in patients with early Alzheimer's disease

Samantha Budd Haeberlein, PhD[1], Carmen Castrillo-Viguera, MD[1], Tianle Chen, PhD[1], John O'Gorman, PhD[1], Raj Rajagovindan, PhD[1], Dakshaben Patel, PhD[2] Philipp von Rosenstiel, MD[1], Guanfang Wang, PhD[3], Spyros Chalkias, MD[1], LeAnne Skordos PharmD[1], Claudia Prada, MD[1], Christoph Hock, MD[4], Roger M Nitsch, MD[4], Alfred Sandrock, MD, PhD[1]

[1]Biogen, Cambridge, MA, USA, [2]Biogen, Maidenhead, UK, [3]Cytel, Cambridge, MA, USA, [4]Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

3.30 - 3.45 p.m.

LB9 - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer's Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers

Harald Hampel, MD, PhD[1], Mohammad Afshar, MD, PhD[2], Frédéric Parmentier, PhD[2], Coralie Williams, MSc[2], Adrien Etcheto, MSc[2], Federico Goodsaid, PhD[3], Christopher U Missling, PhD[4]

[1]Department of Neurology, Sorbonne University, Paris, France, [2]Ariana Pharma, Paris, France, [3]Regulatory Pathfinders LLC, San Francisco, CA, [4]Anavex Life Sciences Corp., New York, NY

3.45 - 4.00 p.m.

LB10 - Predictive performance of CSF and imaging AD biomarkers in ADNI1/GO/2 MCI participants using the NIA-AA research framework

Leslie M Shaw, PhD[1], Michal Figurski, PhD[1], Susan Landau, PhD[2], William Jagust, MD[2], Clifford R Jack, MD[3], Paul S Aisen, MD[4], Ronald C Petersen, MD[3], Michael W Weiner, MD[5], John Q Trojanowski, MD, PhD[1]

[1]University of Pennsylvania, Philadelphia, USA, [2]University of California, Berkeley, Berkeley, USA, [3]Mayo Clinic, Rochester, USA; [4]University of Southern California, San Diego, USA, [5]University of California, San Francisco, San Francisco, USA

Friday, October 26

4.00 - 4.30 p.m. Coffee break and poster session

4.30 - 5.00 p.m.

Keynote 4

Combination therapy in AD

Daniel M. Skovronsky, MD, PhD - Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

5.00 - 6.00 p.m.

Symposium 6

Endpoints for early Alzheimer's disease clinical trials: Interpretation and application of the draft FDA guidance

Symposium moderator: Eric Siemers, MD, Cogstate Ltd, New Haven, CT, USA

Communication 1: Clinical Endpoints in Stage 1, 2 and 3 Disease
Reisa Sperling, MD[1], Ronald C. Petersen, MD, PhD[2], Gary Romano, MD, PhD[3], Paul Maruff, PhD[4]
[1]Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA, [2]Department of Neurology, Mayo Clinic, Rochester, MN, USA, [3]Janssen R&D, Titusville, NJ, USA, [4]Cogstate Ltd, Melbourne, Victoria, Australia

Communication 2: Biomarkers in Stage 1, 2 and 3 Disease
Samantha Budd Haeberlein PhD[1], Jose Luis Molinuevo, MD, PhD[2], Christopher C. Rowe, PhD[3], Maria C. Carrillo PhD[4], Clifford R. Jack, Jr., MD[5]
[1]Biogen, Cambridge, MA, USA, [2]BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation and Hospital Clinic-IDIBAPS, Barcelona, Spain, [3]Department of Molecular Imaging, Austin Health, University of Melbourne, Melbourne, Australia, [4]Alzheimer's Association, Chicago, IL, USA, [5]Department of Radiology, Mayo Clinic, Rochester, MN, USA

Communication 3: Approaches to Establishing the Meaningfulness of Treatment Effects
Chris J. Edgar, PhD[1], George Vradenburg, JD[2], Jason Hassenstab, PhD[3]
[1]Cogstate Ltd, London, UK, [2]UsAgainstAlzheimer's and Alzheimer's Disease Patient and Caregiver Engagement (AD PACE), Chevy Chase, MD, USA, [3]Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA

Saturday, October 27

8.30 - 9.15 a.m.

Presentation and panel discussion:
AMBAR (Alzheimer's Management By Albumin Replacement) Phase IIb/III Results

Presentation by Antonio Páez MD, Grifols S.A., Barcelona, Spain

Followed by Panel Discussion with:

Panel discussion moderator: Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA

- Mercè Boada MD, PhD, Fundació ACE, Universitat Internacional de Catalunya, Barcelona, Spain
- Oscar L. Lopez MD, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Zbigniew M. Szczepiorkowski, MD, PhD, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
- Bruno Vellas, MD, PhD, University Hospital, Toulouse, France

9.15 - 9.45 a.m.

Keynote 5
How BIG and GOOD Data are revolutionizing neurodegenerative disease research

Cristina Sampaio, MD, PhD - Chief Medical Officer, CHDI Foundation, Princeton, USA

9.45 - 10.15 a.m.

Coffee break and poster session

10.15 - 11.15 a.m.

Oral communications

10.15 - 10.30 a.m.

OC26 - First longitudinal evaluation of the tau tracer [18F]MK-6240 for the use in clinical trials

Tharick A. Pascoal MD[1], Sulantha Mathotaarachchi MSc[1], Mira Chamoun PhD[2], Joseph Therriault BSc[1], Robert Hopewell PhD[2], Gassan Massarweh PhD[2], Andrea L. Benedet[1], MSc, BSc, Min Su Kang[1], Jean-Paul Soucy MD[1], Serge Gauthier[1], MD, Pedro Rosa-Neto1, MD, PhD

[1]Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada, [2]Montreal Neurological Institute, McGill University, Montreal, Canada

10.30 - 10.45 a.m.

OC27 - Implementation of the NIA-AA research framework: toward a biological definition of Alzheimer's disease in AIBL

Samantha C Burnham[1,2], Preciosa M Coloma[3], Qiao-Xing Li[4], Steven Collins[5], Greg Savage[6], Simon Laws[2], James Doecke[7], Paul Maruff[8], Ralph N Martins[2,9], David Ames[10], Christopher C Rowe[11], Colin L Masters[4], Victor L Villemagne[4,11]

[1]eHealth, CSIRO, Parkville, VIC, Australia, [2]School of Medical Sciences, Edith Cowan University, Joondalup, Australia, [3]Product Development Personalised Health Care - Data Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland, [4]The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia, [5]Department of Pathology, University of Melbourne, Parkville, Australia, [6]Macquarie University, Sydney, Australia, [7]eHealth, CSIRO, Herston, QLD, Australia, [8]Cogstate Ltd., Melbourne, Australia, [9]Macquarie University, North Ryde, Australia, [10]National Ageing Research Institute, Melbourne, Australia, [11]Austin Health, Melbourne, AustraliaBrain Health, Las Vegas, NV, USA

10.45 - 11.00 a.m.

OC28 - The neuroprotective effect of a new photobiomodulation technique on Aβ25-35 peptide-induced toxicity dramatically impact gut microbiota dysbiosis

Jacques Touchon, MD, PhD[1,2], Laura Auboyer, PhD[3], Johann Meunier, PhD[4], Laura Ceolin, PhD[4], François J. Roman, PhD[4], Rémy Burcelin, PhD[5], Guillaume J. Blivet, MS[3]

[1]Montpellier University, France, [2]INSERMU1061, Montpellier, France, [3]REGEnLIFE SAS, Montpellier, France, [4]Amylgen SAS, Montferrier-sur-Lez, France, [5]Vaiomer SAS, Labège, France

Saturday, October 27

11.00 - 11.15 a.m.

OC29 - Elecsys® CSF biomarker immunoassays demonstrate concordance with results of Amyloid-PET imaging in AIBL patient samples

Larry Ward, PhD[1], Samantha C. Burnham, PhD[4,7] Victor L. Villemagne MD[5,6], Qiao-Xin Li, PhD[5], Steven Collins MBBS PhD[5], Christopher J Fowler PhD[5], Ekaterina Manuilova, PhD[2], Monika Widmann, ChTech[3], Stephanie Rainey-Smith PhD[7], Colin L Masters MD[5], James D Doecke, PhD[1,8]

[1]Cooperative Research Council for Mental Health, Melbourne, Vic, Australia, [2]Roche Diagnostics GmbH, Penzberg, Germany, [3]Roche Diagnostics GmbH, Mannheim, Germany, [4]Commonwealth Scientific Industry and Research Organisation/Australian E- Health Research Centre, Parkville, Melbourne, QLD, Australia, [5]The Florey Institute, The University of Melbourne, Parkville, Australia, [6]Austin Health, Department of Molecular Imaging and Therapy, Center for PET, Heidelberg, Victoria, Australia, [7]School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, [8]Commonwealth Scientific Industry and Research Organisation/Australian E- Health Research Centre, Brisbane, QLD, Australia

11.15 - 12.15 p.m.

Symposium 7

Disclosure of Alzheimer's risk biomarkers to cognitively normal older adults

Symposium co-moderators: Athene Lee PhD[1,2] and Jessica Alber PhD[1,2]

[1]Warren Alpert Medical School of Brown University, Providence, RI, USA [2]Butler Hospital, Providence, RI, USA

Communication 1: "Not just a colonoscopy" – cognitively normal older adults reactions to learning an amyloid PET result

Jason Karlawish, MD[1], Kristin Harkins, MPH[2], Emily Largent, JD, PhD[3], Pamela Sankar, PhD[3], Jeff Burns, MD[4], David Sulzer, MD[5], Joshua Grill, PhD[6]

[1]Departments of Medicine, Medical Ethics and Health Policy, and Neurology, University of Pennsylvania, Philadelphia, PA, USA, [2]Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA, [3]Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA, [4]Department of Neurology, University of Kansas, Kansas City, KS, USA, [5]Department of Psychiatry, University of California, Los Angeles, CA, USA, [6]Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA

Communication 2: Remote genetic counseling and disclosure of APOE genotype within the Generation study 1

Elisabeth McCarty Wood, MS[1], Cara Cacioppo, MS[1], Neeraja Reddy, MS[2], Dare Henry-Moss, MPH[1], Demetrios Ofidis, BS[1], Brian L. Egleston, PhD[3], Jason Karlawish, MD[1], J Scott Roberts, PhD[4], Scott Kim, MD, PhD[5], Carolyn Langlois, MA[6], Eric M. Reiman, MD[6], Pierre N. Tariot, MD[6], Jessica B. Langbaum, PhD[6], Angela R. Bradbury, MD[1]

[1]University of Pennsylvania, Philadelphia, PA, USA, [2]Mapmygenome, Navi Mumbai, India, [3]Fox Chase Cancer Center, Philadelphia, PA, USA, [4]University of Michigan, Ann Arbor, MI, USA, [5]National Institutes of Health, Bethesda, MD, USA, [6]Banner Alzheimer's Institute, Phoenix, AZ, USA

Communication 3: Application of an APOE disclosure model at a clinical trial site and the impact of dual disclosure of amyloid PET results

Louisa Thompson, PhD[1,2], Athene Lee, PhD[1,2], Meghan Collier, PhD[1,2], Danielle Goldfarb, MD[1], Brittany Dawson, FNP[2], Stephen Salloway, MD[1,2], Jessica Alber, PhD[1,2]

[1]Warren Alpert Medical School of Brown University, Providence, RI, USA, [2]Butler Hospital, Providence, RI, USA

12.15 - 1.15 p.m.

Lunch and poster session

1.15 - 3.45 p.m.

Oral communications

1.15 - 1.30 p.m.

OC30 - Adult conditional BACE1 knockout mice exhibit axonal organization defects in the hippocampus

Robert Vassar, PhD Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, USA

1.30 - 1.45 p.m.

OC31 - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation

Gustavo A. Jimenez-Maggiora, MBA[1], Rema Raman, PhD[1], Michael S. Rafii, MD, PhD[1], Reisa Anne Sperling, MD[2,3], Jeffrey Lee Cummings, MD[4], Paul S. Aisen, MD[1]

[1]Alzheimer's Therapeutics Research Institute, University of Southern California, San Diego, CA, USA, [2]Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, [3]Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, [4]Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Saturday, October 27

1.45 - 2.00 p.m.

OC32 - Detecting brain amyloid status using fully automated plasma Aβ biomarker assays

Sebastian Palmqvist[1], Shorena Janelidze, PhD[1]; Erik Stomrud, MD PhD[1]; Henrik Zetterberg, MD PhD[2]; Johann Karl, PhD[3]; Niklas Mattsson, MD PhD[1]; Kaj Blennow, MD PhD[2]; Udo Eichenlaub, PhD[3]; Oskar Hansson, MD PhD[1]

[1]Clinical Memory Research Unit, Lund University, Sweden, [2]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden, [3]Roche Diagnostics GmbH, Penzberg, Germany

2.00 - 2.15 p.m.

OC33 - Concordance of florbetapir (18F) PET and Elecsys® β-Amyloid(1-42) CSF immunoassay in the CREAD (BN29552) study of crenezumab in prodromal-to-mild AD

Timo Grimmer, MD[1], Christina Rabe, PhD[2], Mercidita Navarro, PhD[2], David Clayton, PhD[2], Ekaterina Manuilova, MSc[3], Udo Eichenlaub, PhD[3], Jillian Smith, BSc[4], Susanne Ostrowitzki, MD, PhD[2], Lee Honigberg, PhD[2], Tobias Bittner, PhD[5]

[1]Department of Psychiatry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany, [2]Genentech, Inc., South San Francisco, CA, USA, [3]Roche Diagnostics GmbH, Penzberg, Germany, [4]Roche Products Ltd., Welwyn Garden City, UK, [5]F. Hoffmann-La Roche Ltd., Basel, Switzerland

2.15 - 2.30 p.m.

OC34 - Development of Aβ, tau and cognitive changes during the time course of sporadic Alzheimer's disease

Niklas Mattsson, MD, PhD[1], Oskar Hansson, MD, PhD[1], Michael W. Weiner, MD[2], Philip S. Insel, MS[1,2]

[1]Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, [2]Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA

2.30 - 2.45 p.m.

OC35 - U.S. POINTER: Study design and trial kick-off

Laura Baker, Ph.D.[1]; Mark Espeland, Ph.D.[1], Miia Kivipelto, M.D., Ph.D., Gustavo Jimenez-Maggiora, MBA, Martha Clare Morris, Sc.D., Rema Raman, Ph.D., Scott Rushing1, Heather M. Snyder, Ph.D., Jeff Williamson, M.D.[1], Rachel Whitmer, Ph.D., Nancy Woolard [1], Maria C. Carrillo, Ph.D.

[1]Wake Forest School of Medicine On Behalf of the U.S. POINTER Study Team

2.45 - 3.00 p.m.

OC36 - Implications for AD clinical trials and ppportunities to leverage the first Alzheimer's association U.S. National Best Clinical Practice Guidelines for the evaluation of cognitive behavioral syndromes, Alzheimer's disease and related eementias

Alireza Atri, MD/PhD[1,2], Mary Norman, MD[3], David S. Knopman, MD[4], Jason Karlawish, MD[5], Mary Sano, Ph.D.[6], Carolyn Clevenger, DNP[7], Chiadi U Onyike, MD, MHS[8], Susan Scanland, MSN, CRNP, GNPBC[9], Paige Lin, PhD[10], James Hendrix, PhD[11], Maria C. Carrillo, Ph.D.[11], Brad C. Dickerson, MD[12] and Alzheimer's Association Best Clinical Practices Workgroup

[1]Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA, [2]Center for Brain/Mind Medicine, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, [3]Erickson Living, Dallas, TX, USA,, [4]Mayo Clinic, Rochester, MN, USA, [5]University of Pennsylvania, Philadelphia, PA, USA, [6]James J. Peters VA Medical Center, New York, NY, USA, [7]Emory University, Atlanta, GA, USA, [8]Johns Hopkins University, Baltimore, MD, USA, [9]Dementia Connection, Clarks Summit, PA, USA, [10]Tufts Medical Center, Boston, MA, USA, [11]Alzheimer's Association, Chicago, IL, USA, [12]Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA

3.00 - 3.15 p.m.

OC37 - Pros and cons of AD composite endpoints considering recently revised regulatory guidance and 2018 NIA-AA research framework

Michael T. Ropacki, PhD[1], Suzanne Hendrix, PhD[2]

[1]Strategic Global Research & Development, Half Moon Bay, USA, [2]Pentara Corporation, Salt Lake City, USA

3.15 - 3.30 p.m.

OC38 - The European Prevention of Alzheimer's Dementia (EPAD); Summary of First Formal Data Lock (EPAD V500.0) and predictors of amyloid status

Craig Ritchie, MD, PhD, Centre for Dementia Prevention, University of Edinburgh UK

3.45 p.m. End of conference

CTAD 2018

POSTERS PRESENTATION

- **Theme 1. Clinical trials: Methodology** — pages 22 - 24
  P21, P45, P54, P59, P61, P82, P86, P90, P91-P101 and LBP1 to LBP12
- **Theme 2. Clinical trials: Results** — pages 25 - 27
  P7, P12, P13, P15-P18, P36, P80, P109-P112 and LBP13 to LBP21
- **Theme 3. Clinical trials: Imaging** — pages 28 - 29
  P10, P35, P62, P76, P113-P124 and LBP21 to LBP24
- **Theme 4. Clinical trials: Biomarkers including plasma** — pages 30 - 34
  P1, P4, P22, P28, P30, P39, P44, P57, P64-P66, P73, P78, P81, P125-P130 and LBP25 to LBP40
- **Theme 5. Clinical trials: Cognitive and functional endpoints** — pages 35 - 38
  P2-P3, P8-P9, P19, P25-P27, P53, P67, P69, P71, P74, P77, P83, P140-P144, PP146-149 and LBP41 to LBP46
- **Theme 6. Cognitive assessment and clinical trials** — pages 39 - 42
  P6, P14, P24, P29, P33-P34, P41-P42, P47-P52, P55, P63, P68, P70, P72, P75, P87-P89, P151-P159, P162 and LBP47 to LBP52
- **Theme 7. Behavioral disorders and clinical trials** — page 43
  P32, P37, P43, P163 and LBP53
- **Theme 8. Health economics and clinical trials** — page 44
  P17, P40, P58, P164
- **Theme 9. Epidemiology and clinical trials** — pages 45 - 46
  P17, P38, P46, P165-P168 and LBP54 to LBP56
- **Theme 10. Clinical Trials: Animal Models** — page 47
  P102-P104 and LBP58
- **Theme 11. New therapies and clinical trials** — pages 48 - 49
  P5, P11, P20, P23, P56, P60, P79, P84-P85, P105-P108 and LBP59 to LBP62

Theme 1. Clinical trials: Methodology

P21 - Patterns of MMSE subtest scores in amyloid-positive and -negative participants in J-ADNI

Ryoko Ihara, MD[1], Kazushi Suzuki, MD[1], Atsushi Iwata, MD[2], Takeshi Iwatsubo, MD[1,3], the Japanese Alzheimer's Disease Neuroimaging Initiative

[1]The Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan, [2]Department of Neurology, The University of Tokyo, Tokyo, Japan, [3]Department of Neuropathology, The University of Tokyo, Tokyo, Japan

P45 - Innovations in care community-based recruitment to clinical trial research

Jacobo Mintzer, MD, MBA[1], Mike Splaine[2], Erin Beck, MPH[3]

[1]Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA,, [2]Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, [3]Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P54 - Validation of alzheimer's biomarkers: β-amyloid 1-42 and total tau in CSF by automated CLEIA on lumipulse g 1200 platform

Satya Nandana Narla[1], Amanda Dider[1], Ming Hu[1], Tina LV[2], Yuan Xueling[2] and Martine Florent[1]

[1]Immunology Department, Covance Central Laboratories, Indianapolis, USA, [2]Immunology Department, Covance Central Laboratories, Shanghai, China

P59 - The impact of frailty on the risk of screen failure in randomized controlled trials on Alzheimer's disease

Alessandro Trebbastoni, MD, PhD[1], Marco Canevelli, MD, PhD[1], Giuseppe Bruno, MD[1], Carlo de Lena, MD[1], Letizia Imbriano[1], Fabrizia D'Antonio, MD[1], Laura Pieroni[1]

[1]Department of Human Neuroscience, «Sapienza» University of Rome, Italy

P61 - Concierge site services: site-specific support and capacity development improves recruitment performance

Jacobo Mintzer, MD, MBA[1], Mike Splaine[2], Erin Beck, MPH[3]

[1]Research and Innovation Center, Roper St. Francis, Charleston, SC, USA, Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, [2]Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, [3]Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P82 - Meotis3rc: Efficient network for clinical research on cognitive disorders in North and Pas-de-Calais

Catherine Adnet-Bonte, MD[1], Brigitte Leprince[1], Laetitia Breuilh, PhD[2,3], Florence Pasquier, MD, PhD[2,3]

[1]Meotis, Centre Hospitalier Universitaire de Lille, France, [2]Neurology Department, Centre Hospitalier Universitaire de Lille, France, [3]Excellence Laboratory DISTALZ, Inserm U1171, Univ Lille

P86 - Recruiting older Latinos in senior centers with a culturally tailored Alzheimer's presentation

Jaime Perales, PhD[1], MPH; W Todd Moore, MS[1], Mariana Ramírez, LMSW[1]; Linda Lara, BA[2]; Erica Davis, BA[3]; Jason Resendez, MS[4]; Eric D Vidoni, PhD[1]

[1]University of Kansas Medical Center, Kansas-USA, [2]Guadalupe Center, Kansas City-USA, [3]Don Bosco Senior Center, Kansas City-USA, [4]LatinosAgainstAlzheimer's Coalition, Chevy Chase-USAU1171, Univ Lille

P90 - REVERSE-SD: ongoing phase-2b study of neflamapimod designed in accordance with emerging scientific and regulatory concepts of early Alzheimer's disease (AD)

John Alam[1], Kelly Blackburn1, Niels Prins[2,3], Philip Scheltens[2]

[1]EIP Pharma Inc., Cambridge, MA, USA, [2]Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL, [3]Brain Research Center, Amsterdam, NL

P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer's Disease Together with Precision Medicine Genetic Biomarkers

Stephen Macfarlane, MBBS FRANZCP[1], Michael Kornhauser BPharm[1], Ella Modini BSc[1], Harald Hampel, MD PhD[2], Stephan Toutain MS[3], Christopher Missling PhD[3]

[1]HammondCare Dementia Centre, NSW, Australia, [2]Sorbonne University, Paris, France, [3]Anavex Life Sciences Corp., New York, USA

P92 - Impact of genetic testing on clinical trial participation and subject selection, a pilot study

Marieke Cajal-Berman, PhD[1], Jessica Branning[2], Vishnukartik Nitta, MS[2]

[1]Bioclinica Research, Orlando, FL, USA, [2]ClinCloud, Orlando, FL, USA

P93 - The impact of Transcranial Magnetic Stimulation on diagnostic confidence in patients with Alzheimer Disease eligible for clinical trials

Alberto Benussi, MD[1]*, Antonella Alberici, MD[1]*, Clarissa Ferrari, MD[2]*, Valentina Cantoni, MS[1,3], Valentina Dell'Era, MD[1], Rosanna Turrone, MS[1], Maria Sofia Cotelli, MD[4], Giuliano Binetti, MD[2], Barbara Paghera, MD[5], Giacomo Koch, MD[6,7], Barbara Borroni, MD[1], Alessandro Padovani, MD, PhD[1]
*These authors contributed equally to this work.

[1]Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, [2]IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, [3]Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, [4]Neurology Unit, Ospedale Vallecamonica, Esine, Brescia, Italy, [5]Nuclear Medicine Unit, Spedali Civili Brescia, Brescia, Italy, [6]Non Invasive Brain Stimulation Unit, IRCCS Santa Lucia Foundation, Rome, Italy, [7]Stroke Unit, Policlinico Tor Vergata, Rome, Italy

P94 - Applying patient-centred insights to optimize protocol design and increase biomarker collection acceptability in AD trials

Kenneth Stanley[1], Carolina Rubel[1], Lynne Hughes[1]

[1]IQVIA Project Leadership Unit

P95 - CSF biomarkers outcomes in the ETHERAL AD study

Harald Hampel[1,2,3,4], Carlos Buesa[5], Tamara Maes[5], Mabel Arevalo[5], Michele Lufino[5], Roger Bullock[5]

[1]AXA Research Fund & Sorbonne University Chair, Paris, France, [2]Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France, [3]Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225Paris, France, [4]Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, [5]Oryzon Genomics SA, Barcelona, Spain

P96 - EMIF-AD: A unique pan-European platform for large-scale research on biomarkers and risk factors for Alzheimer's Disease

Preciosa M Coloma[1], Stephanie J. B. Vos[2], Isabelle Bos[2], Andy Simmons[3], Rik Vandenberghe[4], Philip Scheltens[5], José Luis Molinuevo[6,7], Flavio Nobili[8], Sebastiaan Engelborghs[9,10], Giovanni Frisoni[11,12], Gaël Chetelat[13], Alberto Lleó[14], Anders Wallin[15], Julius Popp[16,17], Pablo Martinez-Lage[18], Gonzalo Duran-Pacheco[1], Pieter Jelle Visser[2,5], Mark F Gordon[19], Gerald Novak[20]

[1]Personalised Health Care, Data Science, F. Hoffmann-La Roche AG, Basel, Switzerland, [2]Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands, [3]Institute of Psychiatry, Kings College, London, UK, [4]University Hospital Leuven, Leuven, Belgium, [5]Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, [6]Alzheimer's disease & other cognitive disorders unit, Hopsital Clínic-IDIBAPS, Barcelona, Spain, [7]Barcelona Beta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain, [8]Clinical Neurology, Department of Neurosciences (DINOGMI), University of Genoa and IRCCS Polyclinic San Martino Hospital, Genoa, Italy, [9]Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium, [10]Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, [11]University of Geneva, Geneva, Switzerland, [12]IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, [13]Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France, [14]Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, [15]University of Gothenburg, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Gothenburg, Sweden, [16]Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Switzerland, [17]Department of Psychiatry, Uni versity Hospital of Lausanne, Lausanne, Switzerland, [18]CITA-Alzheimer Foundation, San Sebastian, Spain, [19]Teva Pharmaceuticals, Malvern, PA, USA, [20]Janssen Pharmaceutical Research and Development, Titusville, NJ, USA

P97 - Using transcription phenotypes to utilise basket trial methodology from oncology to create new targets in CNS disorders

Roger Bullock[1], David Rotllant[2], Michele Lufino[2], Cristina Mascaro[2], Carlos Buesa[2], Tamara Maes[2], Sonia Gutierrez[2], Marta Valverde[3], Tony Ramos[3]

[1]Oryzon Genomics, Barcelona, Spain, [3]Vall D'Hebron Hospital, Barcelona, Spain

P98 - Can online registers with small amounts of phenotypic data reduce screen failure rates in Alzheimer's disease trials?

Piers Kotting, MBA[1], Kris Beicher[2], Adam Smith[3], Clare Shaw, PhD[2]

[1]University of Exeter Medical School, Exeter, UK, [2]University of Leeds, Leeds, UK, [3]Institute of Neurology, University College London, London, UK

P99 - Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer's disease

Smiljana Ristic, MD[1], Mercè Boada, MD, PhD[2], Nathalie Pross, PhD[1], Danielle Abi-Saab, PsyD[1], Szofia Bullain, MD[1], Mirjana Andjelkovic, PhD[1], Paul Delmar, PhD[1], Carsten Hofmann, PhD[1], Alison Searle, BSc[3], Monika Baudler, PhD[1], Paulo Fontoura, MD, PhD[1], Rachelle Doody, MD, PhD[4]

[1]F. Hoffmann-La Roche Ltd., Basel, Switzerland, [2]Barcelona Alzheimer Treatment and Research Center, Barcelona, Spain, [3]Roche Products Ltd., Welwyn Garden City, UK, [4]Genentech, Inc., South San Francisco, CA, USA

P100 - Study enrollment and Alzheimer's disease pathology in relation to cohort type and participant characteristics in the EPAD Registry

Lisa Vermunt, MD[1], Graciela Muniz-Terrera, PhD[2,3,4], Lea ter Meulen, MSc[1], Colin Veal, PhD[5], José Luis Molinuevo, MD, PhD[6], Pierre-Jean Ousset, MD[7,8], Niels D Prins, MD, PhD[1,9], David Porteous, PhD[2], Craig W Ritchie, PhD[2], Philip Scheltens, MD, PhD[1], Gerald Luscan, MSc[10], Anthony J Brookes, PhD[5], Pieter Jelle Visser, MD, PhD[1,11]

[1]VU University Medical Center, Amsterdam, Netherlands, [2]University of Edinburgh, Edinburgh, Scotland, [3]University of Victoria, Victoria, Canada, [4]University of Cambridge, Cambridge, England, [5]University of Leicester, Leicester, England, [6]Barcelona Beta Research Center, Barcelona, Spain, [7]Clinic University Hospital, Barcelona, Spain, [8]CHU Toulouse, Gérontopôle and INSERM UMR 1027, Toulouse, France, [9] Brain Research Center, Amsterdam, Netherlands, [10]Pfizer, Paris, France, [11]Maastricht University, Maastricht, Netherlands

P101 - The effects of participant characteristics and selection criteria on Alzheimer disease clinical trial outcomes

Richard E. Kennedy, MD, PhD[1], Guoqiao Wang, PhD[2], Mackenzie E. Fowler, MPH[3], Gary R. Cutter, PhD[4], Lon S. Schneider, MD, MS[5]

[1]Department of Medicine, University of Alabama at Birmingham, USA, [2]Division of Biostatistics, Washington University, St. Louis, USA, [3]Department of Epidemiology, University of Alabama at Birmingham, USA, [4]Department of Biostatistics, University of Alabama at Birmingham, USA, [5]Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA

Late Breaking Posters

LBP1 - Harnessing the power of big data and technology innovations to advance Alzheimer's disease clinical development

Olga Uspenskaya-Cadoz[1], Yuliya Nigmatullina[2], Kenneth Stanley[3], Chaitanya Alamuri[2], Penny Randall[1], Sam Khinda[3], Lanhui Wang[2], Mengting Yang[2], Carolina Rubel[3], Lynne Hughes[3], Tao Cao[2], Michelle O'Keefe[2], Nikhil Kayal[2]

[1]IQVIA CNS Center of Excellence; [2]IQVIA Analytics Center of Excellence; [3]IQVIA Project Leadership

LBP2 - Course correction in A4: implementation of dose escalation

Karen Holdridge, MPH[1], Roy Yaari, MD[1], Brian A. Willis, PhD[1], Isabella Velona, MS[1], Paul Aisen, MD[2], Reisa Sperling, MD[3]

[1]Eli Lilly and Company, Indianapolis, USA, [2]University of Southern California, San Diego, USA, [3]Brigham and Women's Hospital, Boston, USA

LBP3 - Dose escalation in the DIAN-TU solanezumab arm. Was solanezumab in mild to moderate AD dementia too little, too late?

Karen Holdridge, MPH[1], Roy Yaari, MD[1], Brian A. Willis, PhD[1], Isabella Velona, MS[1], Susan Mills[2], Randall Bateman[2]

[1]Eli Lilly and Company, Indianapolis, USA, [2]Washington University, Saint Louis, USA

LBP4 - Does the US have enough clinical trials sites to keep up with the demand of new chemical and device compounds entering the NDA?

Sean Stanton[1], Dan Davis[4], Vishnukartik Nitta, MS[2], Jessica Branning, BS[2], John Dwyer, JD[3], Jason Bork, MBA[3], James Taylor[5], and George Vradenburg, JD[6]

[1]LifeCore Solutions, LLC, [2]ClinCloud, LLC, [3]Global Alzheimer's Platform, [4]Bioclinica Research, [5]Independent Consultant, Caregiver

LBP5 - Goal Attainment Scaling scores, without defined attainment levels, were associated with standardized measures in people with vascular and mixed dementia

Kenneth Rockwood[1,2], Justin Stanley[1], Taylor Dunn[1], Susan E Howlett[1,2]

[1]DGI Clinical Inc., Halifax, NS, Canada, [2]Dalhousie University, Halifax, NS Canada

LBP6 - Consultation for Alzheimer's disease prevention: an effective recruitment strategy for preventive trials

Isabelle Carrie, PhD[1], Julien Delrieu, MD[1,2,3], Françoise Lala, MD[1], Christophe Hein, MD[1], Delphine Pennetier, PhD[1], Pierre Jean Ousset, MD[1,2,3], Bruno Vellas, MD, PhD[1,2,3]

[1]Gerontopole, Toulouse University Hospital, Toulouse-France, [2]Inserm Unit 1027, Toulouse, France, [3]University of Toulouse III, Toulouse, France

LBP7 - Finding a common baseline: Insights from latent disease-time progression modeling in Alzheimer's disease

Lars Lau Raket, PhD[1]

[1]H. Lundbeck A/S, Denmark

LBP8 - The use of Machine Learning algorithms in Clinical Trials on Alzheimer's Disease

Delia A. Gheorghe, MSc[1], Sarah Bauermeister, PhD[1], John Gallacher, PhD[1]

[1]University of Oxford, Department of Psychiatry, Oxford, UK

LBP9 - Predicting cerebral amyloid status and cognitive performance in cognitively normal adults

Alette Wessels, PhD[1], Adrian Schembri, DPsych[2], Pav Kalinowski, PhD[2], Reisa Sperling, MD[3], Roy Yaari, MD[1], Paul Aisen, MD[4], David Barfield, MS[1], Scott Andersen, MS[1], John R. Sims, MD[1], A4 Study Team, Paul Maruff, PhD[2]

[1]Eli Lilly and Company, Indianapolis, IN, USA, [2]Cogstate Ltd, New Haven, Connecticut, CT, USA, [3]Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, [4]Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego

LBP10 - Novel patient identification and pre-screening model improves patient recruitment and retention and reduces screen-failure rates for AD clinical trials

Lucianne Dobson PhD[1], Miguel Rosa Grilo MD[1], Catherine Mummery PhD, FRCP[1]

[1]Dementia Research Centre, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

LBP11 - Delivery of a Patient Focused In-Trial Online Community in a Multi-Year Alzheimer's Disease Study

Adam Butler[1], Denis Curtin, PhD[1], Mackenzie Johnson[1], and Jeff Lee[1]

[1]CRF Bracket, Arlington, VA, USA

LBP12 - Multi-crossover randomized controlled trial designs in Alzheimer's disease

Steven E. Arnold, MD[1], Rebecca A. Betensky, PhD[2]

[1]Massachusetts General Hospital and Harvard Medical School, Boston, USA, [2]Harvard T.H. Chan School of Public Health, Boston, MA

Theme 2. Clinical trials: Results

P7 - Effects of vortioxetine on cognitive functions in patients with Alzheimer's disease and depressive symptoms: interim results of an observational study

Eduardo Cumbo MD[1], Silvia Cumbo MD[1], Salvatore Torregrossa PsyD[1], Daniela Migliore PsyD[1]

[1]Neurodegenerative Disorders Unit, ASP, [2]Caltanissetta, Caltanissetta (Italy)

P12 - Critical Path for Alzheimer's Disease (CPAD) consortium's vision for an aggregated, standardized, and actionable global Alzheimer disease clinical trial database

Volker D. Kern, PhD[1], Stephen P. Arneric, PhD[1], Maria C. Carrillo, PhD[2], James Hendrix, PhD[2], Billy Dunn, MD[3], Stacie Weninger, PhD[4], Jeffrey A. Kaye, MD[5], Daniel R. Karlin, MD[6], Lisa H. Gold, PhD[7], Michael Gold, MD[8], Samantha Budd Haeberlein, PhD[9], Molly Shea, PhD[10], George Vradenburg11, Daniela J. Conrado, PhD[1], and Klaus Romero, MS, MD[1]

[1]Critical Path for Alzheimer's Disease Consortium, Critical Path Institute, Tucson, AZ, USA, [2]Alzheimer's Association, Chicago, IL, USA, [3]U.S. Food and Drug Administration, Silver Spring, MD, USA, [4]F-Prime Biomedical Research Initiative, Cambridge, MA, USA, [5]Oregon Health & Science University, Portland, OR, USA, [6]Pfizer, Boston, MA, USA, [7]Merck & Co., Inc., Kenilworth, NJ, USA, [8]AbbVie, North Chicago, IL, USA, [9]Biogen, Cambridge, MA, USA, [10]Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, [11]UsAgainstAlzheimer's, Washington, DC, USA

P13 - Effects of body weight on safety of 23mg donepezil in Alzheimer's disease: A post-hoc analysis of a multicenter, randomized trial

Yun Jeong Hong, MD, PhD[1,2], Hyun Jeong Han, MD, PhD[3], Young Chul Youn, MD, PhD[4], Kyung Won Park, MD, PhD[5], Dong Won Yang, MD, PhD[6], Sang Yun Kim, MD, PhD[7], Hwa Jung Kim, MD, PhD[8], Ji Eun Kim, MD, PhD[9], Jae-Hong Lee, MD, PhD[1], the ODESA study group

[1]Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, [2]Biomedical research institute, Pusan National University Hospital, Pusan, [3]Neurology, Dementia and Neurocognitive Center, Myongji Hospital, Seonam University College of Medicine, Ilsan, [4]Neurology, Chung-Ang University Hospital, Seoul, [5]Neurology, Dong-A University College of Medicine, Busan, [6]Neurology, The Catholic University of Korea, Seoul, [7]Neurology, Seoul National University College of Medicine & Neurocognitive Behavior Center, Seoul National University Bundang Hospital, Seongnam, [8]Preventive Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, [9]Neurology, University of Ulsan College of Medicine, Gangneung Asan Medical Center, Gangneung, Korea

P15 - A single ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of LY3303560, a tau-specific antibody, in healthy volunteers

Stephen Lowe[1], Jeffrey Dage[2], Ann Cleverley[3], Albert Lo[2], Elizabeth S. LaBell[2], Hakop Gevorkyan[4], Stanford Jhee[5], Larry Huffman[2], Boris Calderon[2], Brian A. Willis[2]

[1]Lilly Centre for Clinical Pharmacology, Singapore, [2]Eli Lilly and Co, Indianapolis, IN, [3]Eli Lilly and Co, Erl Wood, UK, [4]California Clinical Trials Medical Group, Inc., [5]PAREXEL Early Phase, Glendale, CA, USA

P16 - CNP520, a novel oral BACE1 inhibitor, has no clinically meaningful effect on QTc interval up to supratherapeutic doses

Stefan Viktor Vormfelde, MD/PhD[1], Nicole Pezous[1], Gilbert Lefèvre, PhD[1], Carine Kolly, PhD[1], Ulf Neumann, PhD[1], Pierre Jordaan, MD[2], Guenter Heimann, PhD[2], Mike Ufer, MD/PhD[1], Ana Graf, MD[2], Eric Legangneux, MD[1]

[1]Novartis Institutes for BioMedical Research, Basel, Switzerland, [2]Novartis Pharma AG, Basel, Switzerland

P18 - Differences in treatment response between males and females with mild-moderate Alzheimer disease being treated with cholinesterase inhibitors

Kenneth Rockwood, MD[1,2], Justin Stanley, BSc[1], Susan E Howlett, PhD[1,2,3]

[1]DGI Clinical Inc., Halifax, NS, Canada, [2]Division of Geriatric Medicine, Dalhousie University, Halifax, NS Canada, [3]Department of Pharmacology, Dalhousie University, Halifax, NS, Canada

P36 - Phase 1 Clinical Studies in Alzheimer's Disease: Cerebrospinal Fluid Oligomer Change and Other Exploratory Outcomes of amyloid β Aggregate-Specific Antibody KHK6640

Marc Cantillon, MD[1], Hiroyuki Shimada, MD, PhD[2], Kenichiro Sugiyama, Phar.B.[3], Wei Sun, Ph.D.[1], Yoshiumi Ouchi, M Eng[3], Katsuyoshi Tsukii, MSc[1], Gemma Clark, RGN RM[4]

[1]Kyowa Kirin Pharmaceutical Development, Inc., USA, [2]Osaka city university hospital, Osaka, Japan, [3]Kyowa Hakko Kirin Co., Ltd., Japan, [4]Kyowa Kirin International plc, UK

P80 - Cumulative aducanumab safety data from PRIME: a randomized, double-blind, placebo-controlled, Phase 1b study

Philipp von Rosenstiel MD[1], Tianle Chen, PhD[1], John O'Gorman, PhD[1], Min Yee, PharmD[1], Carmen Castrillo-Viguera, MD, PhD[1], Claudia Prada, MD[1], Christoph Hock, MD[2], Roger M Nitsch, MD[2], Samantha Budd Haeberlein, PhD[1], Alfred Sandrock, MD, PhD[1]

[1]Biogen, Cambridge, MA, USA, [2]Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

P109 - The action for health in diabetes clinical trial: does a 10-year intensive multidomain lifestyle intervention provide cognitive benefits?

Kathleen M. Hayden, PhD[1], José A. Luchsinger, MD[2]; Stephen R. Rapp, PhD[1]; Delilah R. Cook, CCRP[1]; Rebecca H. Neiberg, MS[1]; Judy L. Bahnson, BA[1]; Tara D. Beckner[1]; Jerry M. Barnes, MA[1]; and Mark A. Espeland, PhD[1] for the Look AHEAD MIND Study Group

[1]Wake Forest School of Medicine, Winston-Salem, USA, [2]Columbia University, New York, USA

P110 - Single and multiple dose safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTL0018318 in healthy volunteers

Tim Tasker MBBS[1], Jan Liptrot PhD[1], Charlotte Bakker PhD[2], Ellen 't Hart PhD[2], Erica Klaassen PhD[2], Samantha Prins MD[2], Thalia van der Doef PhD[2], Mike Walker[2], Giles A. Brown PhD[1], Alastair Brown PhD[1], Miles Congreve PhD[1], Malcolm Weir PhD[1], Fiona H. Marshall PhD[1], David M. Cross PhD[4], Geert Jan Groeneveld MD, PhD[2], Pradeep. J. Nathan PhD[1,3]

[1]Sosei Heptares, Cambridge UK, [2]Centre for Human Drug Research (CDHR), Leiden, Netherlands, [3]Department of Psychiatry, University of Cambridge, UK, [4]Cross Pharma Consulting Limited, Cambridge, UK

P111 - Assessing the psychological and emotional impact of APOE and amyloid disclosure in the API Generation Program: interim findings

Jessica B. Langbaum, PhD[1], Jason Karlawish, MD[2], Scott Roberts, PhD[3], Angela Bradbury, MD[2], Scott Kim, MD, PhD[4], Elisabeth McCarty Wood, MS[2], Carolyn Langlois, MA[1], Fonda Liu PharmD[5], Marie-Emmanuelle PhD[6], Marie-Laure Rouzade-Dominguez, PhD[6], Angelika Caputo, PhD[6], Mauritz Bezuidenhoudt, M.Sc[6], Cristina Lopez-Lopez, MD, PhD[6], Ana Graf, MD[6], Pierre N. Tariot, MD[1], Eric M. Reiman, MD[1]

[1]Banner Alzheimer's Institute, Phoenix, USA, [2]University of Pennsylvania, Philadelphia, USA, [3]University of Michigan, Ann Arbor, USA, [4]National Institutes of Health, Bethesda, USA, [5]Novartis Pharmaceuticals Corporation, East Hanover, USA, [6]Novartis Pharma AG, Basel, Switzerland

P112 - Meta-analysis of two tau aggregation inhibitor Phase 3 trials in mild Alzheimer's disease with low dose hydromethylthionine

Bjoern Schelter, PhD[1,2], Claude Wischik, MD, PhD[1,2]

[1]nstitute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK, [2]TauRx Therapeutics, Aberdeen, UK

Late Breaking Posters

LBP13 - Cognitive and mobility training as preventive measures in cognitively healthy patients and patients with MCI

Carine Federspiel, MD[1,2], Elisabeth Bourkel, PhD[1], Jean-Paul Steinmetz, PhD[1,2]

[1]Centre for memory and mobility, ZithaAktiv, Luxembourg, [2]ZithaSenior, Research&Development, Luxembourg

LBP14 - Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer's Disease: Consistency of Multiple Evaluation Analyses

Daniel Alkon, PhD[1], LJ Wei, PhD[2], Richard Thompson, PhD[3]

[1]Neurotope,Inc, [2]Harvard University, [3]Johns Hopkins University

LBP15 - Enterovirus might be involved in Alzheimer's disease - results from a phase IIa trial evaluating Apovir, an antiviral drug combination

Lars-Olof Wahlund, MD, PhD[1], Lars Lindqvist MD, PhD[2], Mikael Åström MSc, PhL[3], Jacob Westman PhD[4], Roger Bullock MD, PhD[5], Suzanne Hendrix[6], Nina Lindblom, PhD[4]

[1]Karolinska University Hospital, Huddinge, Sweden, [2]Karolinska University Hospital, Huddinge, Sweden, [3]StatCons, Limhamn, Sweden, [4]Apodemus AB, Solna, Sweden, [5]Roger Bullock Consulting Ltd, Swindon, UK, [6]Pentara Corporation, Salt Lake City, USA

LBP16 - A randomized, placebo controlled, repeat dose phase 1 study of COR388 in older healthy volunteers and patients with Alzheimer's disease

Samer Kaba, MD[1], Casey Lynch[1], Mark Ryder, DMD[2], Ira Goodman, MD[3], Steve Thien, MD[4], Steve Dominy, MD[1]

[1]Cortexyme, S. San Francisco, CA, [2]UCSF, San Francisco, CA, [3]Bioclinica, Orlando, FL, [4]Pacific Research Network, San Diego, CA

LBP17 - Souvenaid in cognitive deterioration. Our experience after 5 years of treatment and follow-up

Miquel Aguilar MD. PhD[1] and Paquita Soler. Nurse[1]

[1]Àptima Mutua Terrassa, Catalunya, SPAIN

LBP18 - Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial

Carmen Valcarce, PhD[1], Imogene Dunn, PhD[1], Tom Soeder, MS[2], and Aaron Burstein, PharmD[1]

[1]vTv Therapeutics LLC, High Point, NC, USA, [2]CATO Research Ltd., Durham, NC, USA

LBP19 - Aducanumab 48-month analyses from PRIME, a Phase 1b study in patients with early Alzheimer's disease

Philipp von Rosenstiel, MD[1], Samantha Budd Haeberlein, PhD[1], Carmen Castrillo-Viguera, MD[1], Tianle Chen, PhD[1], John O'Gorman, PhD[1], Raj Rajagovindan, PhD[1], Dakshaben Patel, PhD[2], Guanfang Wang, PhD[3], Spyros Chalkias, MD[1], LeAnne Skordos PharmD[1], Claudia Prada, MD[1], Christoph Hock, MD[4], Roger M Nitsch, MD[4], Alfred Sandrock, MD, PhD[1]

[1]Biogen, Cambridge, MA, USA, [2]Biogen, Maidenhead, UK, [3]Cytel, Cambridge, MA, USA, [4]Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

LBP20 - Lu AF20513, an active immunotherapy against amyloid beta, in development for patients in early stages of Alzheimer's disease

Bjørn Sperling, MD[1], Lars Østergaard Pedersen, PhD[1], Neli Boneva, MD[1], Dorthe Daugaard, MD[1], Yudong Zhao, PhD[1]

[1]H. Lundbeck A/S, Valby, Denmark

LBP21 - Baseline Data from the API Autosomal Dominant Alzheimer's Disease Colombia Trial

Pierre N. Tariot[1]*, Francisco Lopera[2]*, Kaycee M. Sink[3], Nan Hu[3], Heather Guthrie[3], Jillian Smith[4], William Cho[3], Jessica B. Langbaum[1], Ronald G. Thomas[5], Kewei Chen[1], Yi Su[1], Dhruman Goradia[1], Pradeep Thiyyagura[1], Paul S VanGilder[1], Ji Luo[1], Valentina Ghisays[1], Wendy Lee[1], Michael H. Malek-Ahmadi[1], Hillary D. Protas[1], Yinghua Chen[1], Carole Ho[3], Shehnaaz Suliman[3], Sergio Alvarez[5], Yakeel T. Quiroz[6], Robert Paul[7], Silvia Rios Romenets[2]**, Eric M. Reiman[1]**, and the API ADAD Colombia Trial Group

[1]Banner Alzheimer's Institute, Phoenix, AZ, USA, [2]Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, CO, [3]Genentech Inc., South San Francisco, CA, USA, [4]Roche Products Ltd, Welwyn Garden City, UK, [5]University of California, San Diego, CA, USA, [6]Hospital Pablo Tobon Uribe, Medellin, CO, [7]Harvard Medical School and Massachusetts General Hospital, Boston MA, USA

Theme 3. Clinical trials: Imaging

P10 - Diagnostic accuracy of [18F]FC119S PET for identifying Alzheimer's disease

Byung Hyun Byun, MD, PhD[1], Sang Moo Lim, MD, PhD[1]

[1]Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea

P35 - Annual atrophy rate in normal aging from a large single-center cohort in Korea

Yu Yong Choi[1], Byeong C. Kim[2], Seong-Min Choi[2], Kee Hyung Park[3], Kyu Yeong Choi[1], Kun Ho Lee[1,4]

[1]National Research Center for Dementia, Chosun University, Gwangju, South Korea, [2]Department of Neurology, Chonnam National University Hospital, Gwangju, South Korea, [3]Department of Neurology, Gachon University College of Medicine, Incheon, South Korea, [4]Department of Biomedical Science, Chosun University, Gwangju, South Korea

P62 - Impact of cerebral blood flow changes on 18F-florbetaben SUVR. A simulation study

Santiago Bullich, PhD[1] , Norman Koglin, PhD[1] , Susan De Santi, PhD[2], Georg A. Becker, PhD[3], Audrey Perrotin, PhD[1], Aleksandar Jovalekic, PhD[1], Andrew Stephens, MD, PhD[1], Henryk Barthel, MD, PhD[3], Osama Sabri, MD, PhD[3]

[1]Piramal Imaging GmbH, Berlin, Germany, [2]Piramal Pharma Inc., Boston, MA, USA, [3]Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany

P76 - F-AV-1451 in TDP-43 associated frontotemporal dementia

Ruben Smith, MD, PhD[1,] Alexander F Santillo, MD, PhD[1], Maria Landqvist Waldö, MD, PhD[2], Oskar Hansson, MD, PhD[1,3]

[1]Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden, [2]Memory Clinic, Ängelholm Hospital, Ängelholm, Sweden, [3]Memory Clinic, Skåne University Hospital, Malmö, Sweden

P113 - Predicting amyloid burden from cognitive assessment

Donald R. Royall, MD[1-4], Raymond F. Palmer, PhD[3] for the Alzheimer's Disease Neuroimaging Initiative

[1]Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, [2]Department of Medicine, UTHSCSA, San Antonio, Texas, USA, [3]Department of Family & Community Medicine. UTHSCSA, San Antonio, Texas, USA, [4]South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P114 - The triple use of amyloid PET in Alzheimer's disease

Federica Ribaldi, MS[1,2], Moira Marizzoni, PhD[1], Valentina Garibotto, MD[3], Michela Pievani, PhD[1], Giovanni B Frisoni, MD[1,3]

[1]IRCCS Fatebenefratelli, Brescia, Italy, [2]University of Brescia, Brescia, Italy, [3]Geneva University Hospitals, Geneva, Switzerland

P115 - A comparison of cortical reporter regions for longitudinal analysis of 18F-AV1451 PET data

David Scott, PhD[1], Katarzyna Adamczuk, PhD[1], Beth Gorman, BS CNMT[2], Maureen Runkle, BS CNMT R.T.(N.)[2], Joyce Suhy, PhD[1] and the Alzheimer's Disease Neuroimaging Initiative

[1]Bioclinica, Newark, CA, USA, [2]Bioclinica, Philadelphia, PA, USA

P116 - Can tau PET imaging be instrumental in predicting an elevated amyloid level in clinical trials?

Sergey Shcherbinin, PhD[1], Michael J. Pontecorvo, PhD[2], Ming Lu, MD, MS, MPH[2], Michael D. Devous Sr, PhD[2], A. Joshi, PhD[2], Sudeepti Southekal, PhD[2], Emily C. Collins, PhD[1,2], Adam S. Fleisher, MD[2], Mark A. Mintun, MD[1,2]

[1]Eli Lilly & Co, Indianapolis, IN, USA, [2]Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

P117 - Supratentorial white matter is a better reference for longitudinal quantification of [18F]Flutemetamol scans

Gemma Salvadó MSc[1], Chris Foley PhD[2], Elisabetta Grecchi, PhD[2,3], M. Jorge Cardoso, PhD[4,5], Isadora Lopes-Alves, PhD[6], Pawel Markiewicz, PhD[5], Carles Falcon, PhD[1], Mark Battle MSc[2], Adriaan A. Lammertsma, PhD[6], Mark Schmidt, MD, PhD[7], José Luis Molinuevo MD PhD[1], Frederik Barkhof, MD, PhD[5,6], Juan Domingo Gispert, PhD[1]

[1]BarcelonaBeta Brain Research Center, Barcelona, Spain, [2]GE Healthcare, Amersham, United Kingdom, [3]IXICO, London, United Kingdom, [4]King's College London, London, United Kingdom, [5]University College London, London, United Kingdom, [6]VU Medical Center, Amsterdam, The Netherlands, [7]Janssen Pharmaceutica, Beerse, Belgium

P118 - Clinical validation of 18F-PI-2620 for quantification of tau in subjects with Alzheimer's disease

Andrew Stephens[1], Andre Mueller[1], Santiago Bullich[1], Mathias Berndt[1], John Seibyl[2], Olivier Barret[2], Jennifer Madonia[2], Heiko Kroth[3], Andrea Pfeifer[3], Andreas Muhs[3], Gilles Tamagnan[2], Kenneth Marek[2], Ludger Dinkelborg[1]

[1]Piramal Imaging, Berlin, Germany, [2]Invicro, New Haven, USA, [3]AC Immune SA, Lausanne, Switzerland

P119 - Cut-off for 18F-flutemetamol SUVr with white matter reference region

Katarzyna Adamczuk, PhD[1], David Scott, PhD[1], Ben Newton, PhD[3], Joyce Suhy, PhD[1], Michael Egan, MD[2], Cyrille Sur, PhD[2]

[1]Bioclinica, Newark, CA, USA, [2]Merck Sharp & Dohme, Kenilworth, NJ, USA, [3]General Electric Health Care, Amersham, UK

P120 - Amyloid PET Imaging in a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study with UB-311

Hui Jing Yu[1], Hui-Chen Chen[1], Jacob Hesterman[2], Jack Heimann[2], Sean Holmes[2], Alex Whittington[2], Xue Wang[2], Roger Gunn[2], Ajay Verma[1]

[1]United Neuroscience, Inc. Hauppauge, NY, USA, [2]Invicro, A Konica Minolta Company, Boston, MA, USA

P121 - Cortical dopamine depletion and cognition in Lewy bodies disorders: a 123I-FP-CIT single-subject study

Andrea Pilotto[1,2] and Francesca Schiano di Cola[1], MD and, MD; Enrico Premi[1], MD; Roberto Grassol PsyD, Rosanna Turrone[1], PsyD; MD; Stefano Gipponi[1], MD, Andrea Scalvini[1,] MD; Elisabetta Cottini[1], Barbara Paghera[3], Laura Bonanni[4], PhD; MD; Maria Cristina Rizzetti[2], PhD; Barbara Borroni[1], MD; Alessandro Padovani[1], PhD, MD

[1]Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, [2]Parkinson's Disease Rehabilitation Centre, FERB ONLUS S.Isidoro Hospital, Trescore Balneario (BG), Italy, [3]Nuclear Medicine Unit, University of Brescia, Brescia, Italy, [4]Department of Neuroscience Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy

P122 - Very early detection and treatment monitoring of Alzheimer's Disease in the retina by multimode, hyperspectral confocal scanning ophthalmoscopy

Daniel L. Farkas, PhD[1,2] , Fartash Vasefi, PhD[1], Jeanne M. Fontana, MD, PhD[1]

[1]The Brain Window, Inc., Sherman Oaks CA, USA, [2]University of Southern California, Los Angeles CA, USA

P123 - Quantitative Analysis on The Goodness of Harmonization with Multivariate Analysis of Field Strength, Sex, Age and Total Intracranial Volume

Mirza Faisal Beg, PhD[1], Da Ma, PhD[1], Karteek Popori[1], Mahadev, MD[2], Lei Wang, PhD[3]

[1]School of Engineering Science, Simon Fraser University, Vancouver, BC, Canada, [2]Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, [3]Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

P124 - Prescribing Cholinesterase inhibitors in mild cognitive impairment – observations from the Alzheimer's Disease Neuroimaging Initiative

Eddie Stage[1], Diana Svaldi PhD[1], Sophie Sokolow PhD MPharm[2,5,6], Shannon L. Risacher PhD[1], Krisztina Marosi[2], Kwangsik Nho PhD[1], Jerome I Rotter MD[3,4], Andrew J. Saykin PsyD[1], Liana G. Apostolova MD MS[1]

[1]Indiana Alzheimer Disease Center, Indianapolis, IN, USA, [2]UCLA School of Nursing, Los Angeles, CA, USA, [3]Division of Genomic Outcomes, Department of Pediatrics and Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA, [4]Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Los Angeles Biomedical Research Institute, Torrance, CA, USA, [5]UCLA Brain Research Institute, Los Angeles, CA, USA, [6]UCLA Clinical and Translational Science Institute, Los Angeles, CA, USA

Late Breaking Posters

LBP21 - Prediction of Treatment Response to Donepezil using Automated Hippocampal Subfields Volumes Segmentation in Patients with Mild Alzheimer's Disease

Sheng-Min Wang, MD, PhD[1], Yoo Hyun Um, MD, PhD[2], Chang-Uk Lee MD, PhD[3], and Hyun Kook Lim, MD, PhD[3]

[1]Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, [2]St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea, [3]Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

LBP22 - Role of Confluent White Matter Lesions in the progression to Alzheimer's dementia in an Asian Clinic Cohort

Nagaendran Kandiah

National Neuroscience Institute,Singapore

LBP23 - APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Tramiprosate Datasets

Susan Abushakra MD[1], Luc Bracoud MS[2], Joël Schaerer[2], Aidan Power MD[1], John Hey PhD[1], David Scott PhD[3], Joyce Suhy PhD[3], Martin Tolar MD PhD[1] & the Alzheimer Disease Neuroimaging Initiative (ADNI)

[1]Alzheon Inc., Framingham, MA, USA, [2]Bioclinica, Lyon France, [3]Bioclinica, Newark CA, USA

LBP24 - Preliminary characterization of 18F-RO948 PET imaging among cognitively unimpaired and patients with MCI or dementia in the BioFINDER2 study

Gregory Klein[1], Ruben Smith[2], Sebastian Palmqvist[2], Niklas Mattsson[2], Danielle van Westen[2], Olof Strandberg[2], Jonas Jögi[2], Tomas Ohlsson[2], Edilio Borroni[1], Preciosa Coloma[1], Erik Stomrud[2], Oskar Hansson[2]

[1]Roche Pharma Research and Early Development, Basel, Switzerland, [2]Clinical Memory Research Unit, Lund University, Sweden

Theme 4. Clinical trials: Biomarkers including plasma

P1 - Sustained attention and memory tasks with concurrent EEG provide potential biomarkers for mild cognitive impairment

Shani Waninger, Ph.D.[1], Chris Berka1, Amir Meghdadi, Ph.D.[1], David Salat, M.D.[2] and Ajay Verma, M.D., Ph.D.[3]

[1]Advanced Brain Monitoring, Inc., Carlsbad, CA, [2]MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, [3]United Neuroscience, Dublin, Ireland

P4 - High correlation in the Aβ40 and Aβ42 levels in human cerebrospinal fluid as measured by ELISA and HPLC-MS/MS

José A. Allué, PhD, Leticia Sarasa, PhD, Virginia Pérez-Grijalba, PhD, Noelia Fandos, PhD, Pedro Pesini, PhD, Manuel Sarasa, PhD.

Araclon Biotech S.L., Vía Hispanidad 21, 50.009, Zaragoza, Spain

P22 - Cerebrospinal fluid biomarkers in J-ADNI: diagnostic accuracy in AD and predictability of future clinical change in MCI

Kazushi Suzuki MD, PhD[1] , Ryoko Ihara MD, PhD[1], Atsushi Iwata MD, PhD[1], Takeshi Iwatsubo MD, PhD[1], Kenji Ishii MD[2], Takeshi Ikeuchi MD, PhD[3], Ryozo Kuwano MD, PhD[3], Japanese Alzheimer's Disease Neuroimaging Initiative

[1]The University of Tokyo, Tokyo, Japan, [2]Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, [3]Niigata University, Niigata, Japan

P28 - Analytical performance of the Lumipulse® G pTau 181 and Lumipulse® G β-Amyloid 1-40 assays

Manu Vandijck, Martine Dauwe, Rosina Degrieck, Els Huyck, Nathalie Le Bastard, Geert Jannes, Vesna Kostanjevecki

Fujirebio Europe NV, Ghent, Belgium

P30 - Curcumin is Detectable in Human Cerebrospinal Fluid after Oral Administration of Turmeric Extract HSRx-888

Norman Relkin MD, PhD[1], Dan Li PhD[2], Joshua Costin PhD[2], David Wyatt MD[3]

[1]Relkin Consulting LLC, Harrington Park, NJ 07640, [2]HerbalScience Group, Naples FL, USA, [3]Syneos Health, Miami FL, USA

P39 - Diagnostic biomarkers' clinical applicability in early onset Alzheimer's disease

Neus Falgàs[1], Raquel Sánchez-Valle[1], Mircea Balasa[1,2], Sergi Borrego[1], Magdalena Castellví[1], Adrià Tort-Merino[1], Jaume Olives[1], Beatriz Bosch[1], Guadalupe Fernández[1], Franscisco Lomeña[3], Núria Bargalló[4], Albert Lladó[1]

[1]Alzheimer's disease and other cognitive disorders Unit. IDIBAPS. Hospital Clínic de Barcelona, [2]Atlantic Fellow for Equity in Brain Health. Global Brain Health Institute. Trinity College Dublin, Ireland, [3]Nuclear Medicine Department. IDIBAPS. Hospital Clínic de Barcelona, [4]Image Diagnostic Centre. IDIBAPS. Hospital Clínic de Barcelona

P44 - Inverse association between Aβ42/40 plasma ratios and fibrillary amyloid deposition in the brain: results of the FACEHBI study

Itziar de Rojas, MSc[1], Judith Romero, MSc[2], Octavio Rodríguez-Gomez, MD[1], Pedro Pesini, PhD[2], Angela Sanabria, PhD[1], Alba Pérez-Cordon, MSc[1], Carla Abdelnour, MD[1], Isabel Hernández, MD, PhD[1], Maitee Rosende-Roca, MD[1], Ana Mauleón, MD[1], Liliana Vargas, MD[1], Montserrat Alegret, PhD1, Ana Espinosa, PhD[1], Gemma Ortega, PhD[1], Silvia Gil, MD, PhD[1], Marina Guitart, MSc[1], Anna Gailhajane,t MSc[1], Miguel Angel Santos-Santos, MD, PhD[1], Sonia Moreno-Grau, MSc[1], Oscar Sotolongo-Grau, PhD[1], Susana Ruiz, MN[1], Laura Montrreal, MLT[1], Elvira Martín, MSc[1], Esther Pelejà[1], Francisco Lomeña, MD, PhD[3], Francisco Campos, PhD[3], Assumpta Vivas, MD[4], Marta Gómez-Chiari, MD[4], Miguel Angel Tejero, MSc[4], Joan Giménez, MD[4], Virginia Pérez-Grijalba, PhD[2], Marta Marquié, MD, PhD[1], Gemma Monté-Rubio, PhD[1], Sergi Valero, PhD[1], Adelina Orellana, PhD[1], Lluis Tárraga, MSc[1], Manuel Sarasa, PhD[2], Agustín Ruiz, MD, PhD[1], Mercè Boada, MD, PhD[1], on behalf of the FACEHBI study

[1]Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain, [2]Araclon Biotech©. Zaragoza, Spain, [3]Servei de Medicina Nuclear, Hospital Clínic i Provincial. Barcelona, Spain, [4]Departament de Diagnòstic per la Imatge. Clínica Corachan, Barcelona, Spain

P57 - Concordance of the CSF Abeta42/Abeta40 ratio with amyloid-PET in the BioFINDER study

Oskar Hansson MD PhD[1,2], Katharina Zink MSc[3], Simone Wahl PhD[3], Monika Widmann ChTech[4], Sandra Rutz PhD[3], Maryline Simon PhD5, Kaj Blennow MD PhD[6,7], Erik Stomrud MD PhD[1,2]

[1]Clinical Memory Research Unit, Lund University, Malmö, Sweden, [2]Memory Clinic, Skåne University Hospital, Malmö, Sweden, [3]Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany, [4]Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Mannheim, Germany, [5]Centralised & Point of Care Solutions, Roche Diagnostics International, Rotkreuz, Switzerland, [6]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, [7]Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

P64 - Novel pre-analytical protocol for handling of cerebrospinal fluid samples for the analysis of Alzheimer's Disease biomarkers in clinical practice

Oskar Hansson MD PhD[1,2], Erik Stomrud, MD PhD[1,2], Sandra Rutz PhD[3], Valeria Lifke PhD[3], Ekaterina Bauer MBA PhD[3], Udo Eichenlaub PhD[3], Richard Batrla MD PhD[4], Ekaterina Manuilova MSc[4], Mehmet Can Mert PhD[4], Simone Wahl PhD[4], Kaj Blennow, MD, PhD[5,6]

[1]Clinical Memory Research Unit, Lund University, Malmö, Sweden, [2]Memory Clinic, Skåne University Hospital, Malmö, Sweden, [3]Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany, [4]Centralised & Point of Care Solutions, Roche Diagnostics International, Rotkreuz, Switzerland, [5]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, [6]Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

P65 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer's Disease

Shu Yu[1]*, Yue-Ping Liu[2]

*[1]State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of LaboratoryMedicine, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi Province 710000, China, [2]Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province 400013, China, *: Corresponding author*

P66 - TREM2 DNA methylation: A potential biomarker or therapeutic target

Lynn Bekris[1], Rumana Akhter[1], Yvonne Shao[1], Maria Khrestian[1], Giana D'Aleo[1], Shane Formica[1], James B. Leverenz[2]

[1]Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, [2]Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio

P73 - Immune state in cognitive impairment of aged and the use of Actovegin and Ceraxone in out-patients of Alzheimer's centre

Nataliya Mikhaylova[1], Lubov Androsova[2]

[1]MD, PhD Geriatric psyciatry Department, Mental health researc centre, Moscow, Russia, [2]PhD, Immunology laboratory, Mental health research centre, Moscow, Russia

P78 - Modifiable Alzheimer's risk biomarkers

Christine Ganzer[1], Alon Seifan, MD[2], Krista Ryon[3], Elizabeth Maiche MCMSc, PA-C[4]

[1]Hunter College, NY, [2]NeuroWell Free, Ft. Lauderdale, Florida, [3]Hunter College, NY, [4]NeuroWell Free, Ft. Lauderdale, Florida»

P81 - Serum NFL, TAU, GFAP and UCHL-1 in Alzheimer disease patients with different decline profile

Mélissa Jacob, MD[1,2,3], Aleksandra Maceski, PhD[3], Stiene Rickaert PhD[3], Audrey Gabelle MD, PhD[1,2,4], Sylvain Lehmann MD, PhD[2,3]

[1]Memory Research and Resources Center, Department of Neurology, Montpellier University Hospital, Montpellier, France, [2]Université de Montpellier, MUSE, Montpellier, France, [3]Inserm U1183 IRMB, Montpellier, France, [4]Inserm U1061, La Colombière Montpellier University Hospital, Montpellier, France

P125 - An ultra-sensitive molecular immuno-assay for quantification of human SNAP25 in cerebrospinal fluid

Eugeen Vanmechelen, PhD1, Jeroen Vanbrabant, PhD1, Naomi De Roeck, BcS2, Maria Bjerke, PhD2, Sebastiaan Engelborghs, MD, PhD2,3, Ann De Vos, PhD1

[1]ADx NeuroSciences NV, Ghent, Belgium, [2]Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, [3]Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium

P126 - Plasma and CSF biomarkers for the diagnosis of Alzheimer´s disease in adults with Down Syndrome. A cross-sectional study

Maria Carmona-Iragui, MD, PhD[1,2,3], Bessy Benejam, MSc[2], Susana Fernández, MD[2], Laura Videla, MSc[1,2,3], Isabel Barroeta, MD, PhD[1,3], Daniel Alcolea, MD, PhD[1,3], Jordi Pegueroles, MSc[1,3], Laia Muñoz, MSc[1,3], Olivia Belbin, PhD[1,3], Jordi Clarimón, PhD[1,3], Mony John de Leon, Ed.D[4], Sebastián Videla, MD, PhD[2,5], Aleksandra Maleska Maceski, MSc[6], Christophe Hirtz, PhD[6], Constance Delaby, PhD[6], Sylvain Lehmann, PhD[6], Rafael Blesa, MD PhD[1,3], Alberto Lleó, MD, PhD[1,3], Juan Fortea, MD PhD[1,2,3]

[1]Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Spain, [2]Barcelona Down Medical Center. Fundació Catalana de Síndrome de Down, Barcelona, Spain, [3]Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain, [4]New York University School of Medicine, NYU Center for Brain Health, Department of Psychiatry. New York, USA, [5]Clinical Research Support Unit, Bellvitge University Hospital / Bellvitge Biomedical Research Institute (IDIBELL) / University of Barcelona, Barcelona, Spain, [6]Université de Montpellier, CHU de Montpellier, INSERM U1183. Montpellier, France

P127 - The application of Polygenic Risk Score analysis to Stratification of Subjects for Clinical Trials in Alzheimer's Disease in carriers and non-carriers of the ApoE4 risk allele

Richard Pither PhD[3], Ganna Leonenko[1], Rebecca Simms[1], Paula Daunt PhD[3], Greg Davidson PhD[3], Alex Gibson PhD[3], Olusegun Oshota PhD[3], Maryam Shoai PhD[2], Kevin Banks[3], Simon M Laws PhD[4], Zsuzsanna Nagy[6] and John Hardy, PhD, DSc[2], Julie Williams PhD[1,6], Valentina Escott-Price, PhD[1,6]

[1]Cardiff University, Cardiff, United Kingdom, [2]Cytox Ltd, UK, Oxford, United Kingdom, [3]UCL Institute of Neurology, London, United Kingdom, [4]Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia, [5]University of Birmingham, United Kingdom, [6]Dementia Research Institute, Cardiff, United Kingdom

P128 - Do short Aβ-peptides impact the time course of cognitive decline? An ADNI analysis

Markus von Kienlin, PhD[1], Paul Delmar, PhD[1], Katharina Buck, PhD[2], Charlotta Schärfe[2], Simone Wahl, PhD[2], Karlheinz Baumann, PhD[2], Irene Gerlach, PhD[1], Tania Nikolcheva, MD, PhD[1]

[1]pRED NORD, Roche Innovation Center Basel - Switzerland, [2]Biostats and Data Management, Roche Innovation Center Munich - Germany

P129 - Measuring oligomerization tendency of plasma as a new blood-based biomarker for Alzheimer's disease

SangYun Kim, MD, PhD[1,2], Sungmin Kang, MS[3], Seong Soo A. An, PhD[4], Young Chul Youn, MD, PhD[5]

[1]Department of Neurology, Seoul National University College of Medicine, [2]Clinical Neuroscience Center, Seoul National University Bundang Hospital, [3]PeopleBio Company, [4]Department of Bionano Technology,Gachon Medical Research Institute, Gachon University, [5]Department of Neurology, Chung-Ang University College of Medicine

P130 - Transcranial magnetic stimulation predicts cognitive decline in Alzheimer's disease patients

Giacomo Koch MD, PhD[1,2], Caterina Motta MD[2], Francesco Di Lorenzo MD[2], Maria Concetta Pellicciari PhD[2], Sonia Bonnì PhD[2], Silvia Picazio PhD[2], Carlo Caltagirone MD[2], Alessandro Martorana MD[3]

[1]Department of Behavioral and Clinical Neurology, [2]Santa Lucia Foundation IRCCS, Rome, Italy, [3]Univeristy of Tor Vergata, Rome, Italy

P131 - Non-core biomarkers (neurofilament light, neurogranin, 14-3-3 and YKL-40) in the Alzheimer's disease continuum, frontotemporal dementia and prion diseases diagnosis

Anna Antonell, PhD[1], Adrià Tort, MSc[1], José Ríos, MSc[2], Sergi Borrego, MD[1], Mircea Balasa, MD[1], Cristina Muñoz-García[1], Beatriz Bosch, PhD[1], Neus Falgàs, MD[1], Lorena Rami, PhD[1], Kaj Blennow, MD, PhD[3], Henrik Zetterberg, PhD[4,5], José Luis Molinuevo, MD, PhD[1], Albert Lladó, MD, PhD[1], Raquel Sánchez-Valle, MD, PhD[1]

[1]Alzheimer's disease and other cognitive disorders Unit. Hospital Clínic. IDIBAPS. Barcelona, Spain, [2]Medical Statistics Core Facility, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Hospital Clinic. Barcelona. Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, [3]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, [4]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, [5]Department of Molecular Neuroscience, University College London, London, UK

P132 - Amyloid blood biomarker detect Alzheimer's disease

Klaus Gerwert, Prof. Dr.[1]

[1]Ruhr-Universität Bochum, Bochum, Germany

P133 - Early diagnosis of Mild Cognitive Impairment and Alzheimer´s disease based on salivary lactoferrin

Eva Carro[1], Gorka Orive[2]

[1]Networked Biomedical Research Center in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), Madrid, Spain, [2]Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain; Networked Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain

P134 - Exome-sequencing in patients with early-onset Alzheimer's disease and Frontotemporal dementia: causal mutations and genetic variants in risk genes for dementia

Anna Antonell, PhD[1], Raquel Sánchez-Valle, MD, PhD[1], Neus Falgàs, MD[1], Mircea Balasa, MD, PhD[1], Debayan Datta, PhD[2] , Lluís Armengol, PhD[2], Sergi Borrego, MD[1], Guadalupe Fernández1, Beatriz Bosch, PhD[1], Jaume Olives[1], Cristina Muñoz-García[1], María León[1], Magdalena Castellví[1], Adrià Tort[1], Albert Lladó, MD, PhD[1]

[1]Alzheimer's disease and other cognitive disorders Unit. Hospital Clínic. IDIBAPS. Barcelona, Spain, [2]qGenomics (Quantitative Genomic Medicine Laboratories), Esplugues de Llobregat, Spain

P135 - The future of blood-based kinase biomarkers in Alzheimer's disease

Jacques Hugon, Julien Dumurgier, Emmanuel Cognat, Claire Paquet

Center of Cognitive Neurology, Lariboisiere Hospital, AP-HP, University of Paris Diderot, Paris France

P136 - A prototype SIMOA assay quantifying plasma amyloid beta 1-42 and 1-40 isoforms can differentiate AD from healthy control subjects

Charlotte E. Teunissen, PhD[1], Elisabeth Thijssen, MSc[2], Inge M. W. Verberk, MSc[2], Hugo Marcel Vanderstichele, PhD[3], Hans Heijst[2], Harry Twaalfhoven[2], Kimberley Mauroo BSc[3], Philip Scheltens, MD, PhD[4], and Erik Stoops, Eng[3]

[1]Neurochemistry Laboratory and Biobank, Amsterdam University Medical Center, Amsterdam, Netherlands, [2]Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Center Amsterdam, Netherlands, [3]ADx NeuroSciences, Gent, Belgium, [4]Amsterdam University Medical Center, Department of Neurology, Amsterdam, Netherlands

P137 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer's Disease

Shu Yu[1]*, Yue-Ping Liu[2]

*[1]State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi Province China, [2]Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province, China. *: Corresponding author*

P138 - Inflammatory markers tracking cognitive and biomarker heterogeneity in MCI stage of Alzheimer's Disease

Jagan A Pillai MBBS PhD[1,2,3], James Bena MS[4], Lynn M Bekris PhD[5], James B Leverenz MD[1,2,3]

[1]Lou Ruvo Center for Brain Health, [2]Neurological Institute and [3]Department of Neurology, [4]Quantitiave Health Sciences, [5]Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA

P139 - The pitfalls for clinical trials of the use of time points earlier than 90 min for the [18F]MK-6240 SUVR calculation

Tharick A. Pascoal MD[1], Sulantha Mathotaarachchi MSc[1], Mira Chamoun PhD[2], Joseph Therriault BSc[1], Robert Hopewell PhD[2], Gassan Massarweh PhD[2], Andrea L. Benedet[1], MSc, BSc, Min Su Kang[1], Serge Gauthier[1], MD, Pedro Rosa-Neto[1], MD, PhD

[1]Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada

Late Breaking Posters

LBP25 - Discovery of AN Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in Human Brain

John A. Hey[1], Petr Kocis, Jakub Hort[2,3], Susan Abushakra1, Aidan Power[1], Martin Vyhnálek[2,3], Jeremy Y. Yu[1] and Martin Tolar[1]

[1]Alzheon, Inc., Framingham, MA, USA, [2]International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czech Republic, [3]Cognitive Center, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic

LBP26 - Novel use of aptamer libraries for prediction of amyloid status from blood serum

Gregory Penner[1], Soizic Lecocq[1], Anaëlle Chopin[1], Simone Lista[2,3,4,5], Andrea Vergallo[2,3,4,5], Enrica Cavedo[2,3,4,5], Francois-Xavier Lejeune[4], and Harald Hampel[2,3,4,5] the INSIGHT-preAD study group and the Alzheimer Precision Medicine Initiative (APMI)

[1]NeoNeuro SAS, Villejuif Bio Park, Villejuif, France, [2]AXA Research Fund & Sorbonne University Chair, Paris, France, [3]Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Paris, France , [4]Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France, [5]Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France

LBP27 - Novel cerebrospinal fluid synaptic markers in Alzheimer's disease for potential use in clinical trials

Alberto Lleó MD, PhD[1,2], Raúl Núñez-Llaves[2,3], Daniel Alcolea MD, PhD[1,2], Martí Colom-Cadena PhD[2,3], Laia Muñoz[2,3], Marta Querol-Vilaseca[2,3], Jordi Pegueroles[2,3], Lorena Rami PhD[4], Albert Lladó MD, PhD[4], José L. Molinuevo MD, PhD[4], Mikel Tainta MD, PhD[5], Jordi Clarimón PhD[2,3], Tara Spires-Jones PhD[6], Rafael Blesa MD, PhD[1,2], Juan Fortea MD, PhD[1,2], Pablo Martínez-Lage MD, PhD[5], Raquel Sánchez-Valle MD, PhD[4], Àlex Bayés PhD[7,8], Olivia Belbin PhD[2,3]

[1]Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, [2]Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, [3]Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain, [4]Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clínic-Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, [5]Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain, [6]Centre for Discovery Brain Sciences and UK Dementia Research Institute, University of Edinburgh, [7]Molecular Physiology of the Synapse Laboratory, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain, [8]Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain

LBP28 - Diminished platelet-derived hsa-miR-150-5p expression as biomarker for dementia with Lewy bodies versus Alzheimer's disease

Katrin Beyer, PhD[1], Ana Gámez-Valero, PhD[1,2], Jaume Campdelacreu, MD, PhD[3], Dolores Vilas, MD, PhD[4], Lourdes Ispierto, MD, PhD[4], Jordi Gascón-Bayarri, MD[3], Ramón Reñé, MD, PhD[3], Ramiro Álvarez, MD[4], Maria P Armengol, PhD[5], Francesc E. Borràs, PhD[2]

[1]Department of Pathology, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain, [2]REMAR-IVECAT group, Health Sciences Research Institute Germans Trias i Pujol, Badalona, Spain, [3]Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, [4]Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, [5]Genomic and Microscopy facilities, Institut Investigació Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona (Barcelona), Spain

LBP29 - Development of polygenic risk scores (PRS) for common neuropathology

Julie Collens, PhD[1], Mike Nalls, PhD[1], Marcel van der Brug, PhD[1]

[1]Vivid Genomics, Inc. San Diego, CA, USA

LBP30 - The Italian Inter-Societal consensual algorithm for the biomarker-based diagnosis of mild cognitive impairment

Marina Boccardi, PhD[1,2], Valentina Nicolosi, MS[1], Cristina Festari, MS[1,3], Angelo Bianchetti, MD[4,5], Stefano Cappa, MD[1,6,7], Davide Chiasserini, PhD[8,9], Andrea Falini, MD[10-13], Ugo Paolo Guerra, MD[14,15], Flavio Nobili, MD[15-17], Alessandro Padovani, MD[7,18], Giulia Maria Sancesario, PhD[9,19], Francesca Benedetta Pizzini, PhD[13,20], Alberto Beltramello, MD[13,21], Marcello Ciaccio, MD[9,22], Orazio Schillaci, MD[15,23], Marco Trabucchi, MD[5,24], Fabrizio Tagliavini, MD[25], Giovanni Battista Frisoni, MD[1,2,26]

[1]Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, [2]LANVIE, Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland, [3]University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italy, [4]Medicine and Rehabilitation Department, Istituto Clinico S. Anna, Brescia, Italy, [5]Italian Psychogeriatric Association (AIP), Brescia, Italy [6]NEtS Center, Scuola Universitaria Superiore IUSS, Pavia, Italy, [7]Italian Society of Neurology, Association for the Study of the Dementias (SINdem), Italy, [8]Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy, [9]Italian Society of Clinical Biochemistry and Clinical Molecular Biology, Laboratory Medicine (SIBioC), Italy, [10]Division of Neuroscience, IRCCS San Raffaele, Milan, Italy, [11]Vita-Salute San Raffaele Università, Milan, Italy, [12]Neuroradiology Unit, IRCCS San Raffaele hospital, Milan, Italy, [13]Italian Association of Neuroradiology (AINR), Italy [14]Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy, [15]Italian Association of Nuclear Medicine (AIMN), Italy, [16]Clinical Neurology, Dept of Neuroscience (DiNOGMI), University of Genoa -Italy, [17]IRCCS Ospedale Policlinico San Martino, Genova, Italy, [18]Neurology Clinic, Department of Clinical and Experimental Sciences, Brescia, Italy, [19]Department of Clinical and Behavioural Neurology, Santa Lucia Foundation, Rome, Italy, [20]Department of Neuroradiology, General Hospital, Verona, Italy, [21]Dipartimento di Diagnostica per Immagini, IRCCS Ospedale Classificato «Sacro Cuore - Don Calabria», Negrar, Verona, [22]Department of Biopathology and Medical Biotechnologies, University of Palermo, Palermo, Italy, [23]Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy [24]Tor Vergata, Rome University, Rome, Italy, [25]Division of Neurology V/Neuropathology, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy, [26]Memory Clinic, University Hospital, Geneva, Switzerland

LBP31 - Secondary structure of Aβ as blood biomarker

Klaus Gerwert Department of Biophysics Ruhr University Bochum, Germany

POSTERS PRESENTATION

LBP32 - BDNF as a biomarker for the effects of p38 MAPKα inhibition on IL-1β-induced impairment of hippocampal synaptic plasticity

John Alam MD[1], Charlotte Teunissen PhD[2], Niels Prins MD PhD[3,4], Hui-May Chu PhD[5], Philip Scheltens MD PhD[3]

[1]EIP Pharma Inc, Cambridge MA, USA, [2]Department of Clinical Chemistry, VU University Medical Center, Amsterdam, NL, [3]Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL, [4]Brain Research Center, Amsterdam, NL, [5]Anoixis Corporation, Framingham MA, USA

LBP33 - Impact of pre-analytical sample handling on Elecsys Aβ40, Aβ42 and tTau immunoassays in plasma

Malgorzata Rozga, PhD[1], Tobias Bittner, PhD[2], Richard Batrla-Utermann, MD, MBA[3], Johann Karl, PhD[1]

[1]Roche Diagnostics GmbH, Penzberg, Germany, [2]Genentech, A member of the Roche Group, Basel, Switzerland, [3]Roche Diagnostics International AG, Rotkreuz, Switzerland

LBP34 - Agreement between visual amyloid PET and cerebrospinal fluid Aβ1-42, Aβ1-40, t-Tau and p-Tau on the LUMIPULSE G fully automated platform

Alberto Lleó[1,2], Jordi Pegueroles[1,2], Laia Muñoz[1,2], Valle Camacho[3], Diego López-Mora[3], Alejandro Fernández-León[3], Nathalie Le Bastard[4], Els Huyck[4], Alicia Nadal[5], Verónica Olmedo[5], Víctor Montal[1,2], Eduard Vilaplana[1,2], Rafael Blesa[1,2], Juan Fortea[1,2], Daniel Alcolea[1,2]

[1]Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, [2]Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Spain, [3]Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, [4]Fujirebio Europe NV, Gent, Belgium, [5]Fujirebio Iberia, SLU, Barcelona, Spain

LBP35 - Does non-disclosure of APOE genotyping prevent subject interest or participation in clinical trials?

Sean Stanton[1], Vishnukartik Nitta, MS[2], Jessica Branning, BS[2]

[1]LifeCore Solutions, Winter Park, USA, [2]ClinCloud, LLC, Orlando, USA

LBP36 - Measurement of pathological amyloid in a patient cohort in routine clinical assessment: comparison of visual [18F]Flutemetamol PET read and CSFs measures

Nenad Bogdanovic[1], Enrico Fantoni[2] & Gill Farrar[2]

[1]Karolinska Institutet, Stockholm, Sweden and University Hospital Oslo, Oslo University, Norway, [2]GE Healthcare Life Sciences. Amersham, UK and Boston, USA

LBP37 - Kinetic measurement of newly generated BACE1-cleaved APP in the human central nervous system in Alzheimer's disease: a pilot study

Robert J. Vassar, PhD[1], Randall J. Bateman, MD[2], Bruce W. Patterson, PhD[3], Justyna A. Dobrowolska Zakaria, PhD[1]

[1]Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA, [2]Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA, [3]Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA

LBP38 - Reliability of a rapid APOE assay for Alzheimer's risk assessment and clinical trial screening

Athene Lee, PhD[1,2], William Menard, BA[2], Gina Tonini, MBA[2], Louisa Thompson, PhD[1,2] Jessica Alber, PhD[1,2] Stephen Salloway, MD[1,2]

[1]Warren Alpert Medical School of Brown University, Providence, RI, USA, [2]Butler Hospital, Providence, RI, USA

LBP39 - Cerebrospinal fluid profiling of multiple pathophysiological pathways in Alzheimer's disease

Steven Arnold MD, PhD[1] Bianca A. Trombetta[2] Becky C. Carlyle, PhD[2]

[1]Massachusetts General Hospital and Harvard Medical School, [2]Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

LBP40 - Interim biomarker analyses of phase II study data on safety and efficacy of GMCSF in mild-to-moderate Alzheimer's disease

Timothy D. Boyd, PhD[1,2], Jonathan Woodcock, MD[1,3], Stefan Sillau, PhD[1,3], Vanesa Adame, BS[1,2], Thomas Borges, MD[1,4], Ashesh Thaker, MD[1,4], Brianne Bettcher, PhD[1,5], Joseph Daniels, MS[1,3], Kate Heffernan, BS[1], Huntington Potter, PhD[1,2,3]

[1]Rocky Mountain Alzheimer's Disease Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, [2]Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, [3]Department of Neurology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, [4]Department of Radiology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, [5]Department of Neurosurgery, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA

Theme 5. Clinical trials: Cognitive and functional endpoints

P2 - Objectively measured physical activity and cognitive function

Hiroyuki Umegaki[1], Taeko Makino[2], Kazuki Uemura[3], Hiroyuki Shimada[4], Xian Wu Cheng[5]

[1]MD, PhD Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan, [2]PhD Institute of Innovation for Future Society, Nagoya University, Aichi, Japan, [3]Liberal Arts and Sciences, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan, [4]Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan, [5]PhDb, Masafumi Kuzuya, MD, PhD, Institute of Innovation for Future Society, Nagoya University, Aichi, Japan

P3 - D-Cycloserine improves difficult discriminations in a pattern separation task in Alzheimer's disease: Implications for dentate gyrus activity and neurogenesis

Pascal J. D. Goetghebeur[1], Keith A. Wesnes[2], Steven D. Targum[3]

[1]Bracket LLC, Reading, UK. [2]Wesnes Cognition Ltd, Streatley on Thames, UK. [3]Bracket LLC, Boston, US

P8 - A Multicenter, Open-label, 24-week Follow-up Study for Efficacy on Cognitive Function of Donepezil in Binswanger-Type Subcortical Vascular Dementia

Jay Cheol Kwon, M.D.[1], Eung Gyu Kim, M.D.[2], Jae Woo Kim , M.D.[3], Oh Dae Kwon, M.D.[4], Bong Goo Yoo M.D.[5], Nam-Gon Kim, M.D.[6], Nack Cheon Choi, M.D.[7], Seon young Ahn, M.A., Byung Hwa Lee, M.D.[8], Myong Jin Kang, M.D.[9], Dae Seob Choi, M.D[10], The BKVD Study Group

[1]Department of Neurology, Changwon Fatima Hospital, [2]Inje University Pusan Paik Hospital, [3]Dong-A University Medical Center, [4]Daegu Catholic University Medical Center, [5]Kosin University Gospel Hospital, [6]Gimhae Jungang Hospital, [7]Gyeongsang National University Hospital, [8]Department of Radiology, [9]Dong-A University Medical Center, [10]Gyeongsang National University Hospital

P9 - The Correlation of Diabetic Status, Ischemic and Atrophic Burdens on Brain MRI and Cognitive Decline in Seventh Decade Diabetic Patients with Cognitive Impairment. -1 Year Prospective, Observational Study

Jay Choel Kwon, MD, PhD. , Kyungsoo Lee, MD, Yohan Jung, MD, PhD. , Sungrae Cho, MD, PhD. And Nack-cheon Choi, MD, PhD.

[1]Changwon Fatima Hospital, Changwon, Korea, The Republic of, [2]Samsung Changwon Hospital, Changwon, Korea, The Republic of, (3)Gyeongsang National University Hospital, Chinju, Korea, The Republic of

P19 - Lanabecestat: Central monitoring of rater performance and error characteristics of efficacy assessments in the AMARANTH study

Alette M. Wessels[1], Lisle R. Kingery[2], Edward I. Bartolic[2], Laura E. Nickell1, Jamie A. Mullen[3], John R. Sims[1]

[1]Eli Lilly and Company, Indianapolis, IN, USA, [2]Cogstate, New Haven, USA, [3]AstraZeneca Pharmaceuticals, Cambridge, MA, USA

P25 - Effects of sex, educational background, and CKD grading on cognitive and functional decline in Japanese ADNI study

Atsushi Iwata, MD[1], Ryoko Ihara, MD[2], Kazushi Suzuki, MD[2], Takeshi Iwatsubo, MD[2], and the Japanese ADNI[1]

[1]Department of Neurology, The University of Tokyo Hospital, Tokyo, Japan, [2]Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital Tokyo, Japan

P26 - A German version of the "Five Word Test" – Discriminating patients with mild cognitive impairment/mild Alzheimer's disease, healthy controls and patients with depression

Hausner L, MD, Dinu-Biringer R, PhD, Frölich L, MD, PhD

Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany

P27 - Use of Medications on Transcranial Doppler Vasoreactivity in Mild Cognitive Impairment

Shim YongSoo, Jung San

Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea, Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

P53 - MMSE screening data quality for Alzheimer's disease studies across countries

Jordan Mark Barbone, BA[1], Todd M. Solomon, PhD[1,2], H. Todd Feaster, PsyD[1], Macarena Garcia-Valdecasas Colell, MSc[3], & David S. Miller, MD, MA[1]

[1]Bracket, Wayne, PA, USA, [2]Boston University School of Medicine, Boston, MA, USA, [3]Bracket, Reading, UK

P67 - The presence of identical scoring on the MMSE and ADCS-ADL in Alzheimer's disease clinical trials using enhanced eCOA devices

Todd M. Solomon., Ph.D[1,2]., Jordan Mark Barbone, B.A[1], Sarah M. Karas, Psy.D[1], Danielle T. DiGregorio, Psy.D[1], Michael R. Maddock[1], MA David M. Miller, MD[1], H. Todd Feaster, Psy.D[1]

[1]Bracket, Wayne, PA, USA, [2]Boston University School of Medicine, Boston, MA USA

P69 - Neuroplasticity-based visual alertness training and improvements in declining executive functions in healthy older adults

Thomas Van Vleet, PhD[1], Joseph DeGutis, PhD[2,3], Michelle Voss, PhD[4]

[1]Research and Development, Posit Science, San Francisco, CA, USA, [2]School of Medicine, Harvard University, Boston, MA, USA, [3]Boston VA, Boston, MA, USA, [4]Psychology Department, University of Iowa, Iowa City, IA, USA

P71 - The treatment response of Goal Attainment Scaling in relation to goal number in a clinical trial of Alzheimer's Disease Patients

Kenneth Rockwood, MD[1,2], Lisa McGarrigle, PhD[1,2]

[1]Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, [2]DGI Clinical Inc., Halifax, NS, Canada

P74 - Predictive value and test-retest reliability of the tablet-based Brief Assessment of Cognition (BAC App) for assessment of cognition in aging: preliminary findings from an ongoing normative study

Anzalee Khan PhD[1,2], Danny Ulshen BA[1], Alexandra Atkins PhD[1], Danela Balentin BA[1], Adam Vaughan PhD[1], Heather Dickerson PhD[1], Brenda L. Plassman PhD[3], Kathleen A. Welsh-Bohmer PhD[3], Rich Keefe PhD[1,3]

[1]NeuroCog Trials, Durham, NC, USA, [2]Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA, [3]Duke University, Durham, NC, USA

P77 - Clinical and Amyloid Screen Failure Rates in Episodic Memory Measures of Early AD Trials

Selam Negash[1], Christopher Weber[1], Christopher Randolph[1,2]

[1]MedAvante-ProPhase, [2]Loyola University Medical Center

P83 - Determinants of care refusal: from patients suffering from dementia to their caregivers characteristics'

Gaëstel, Y, Phd, CERDA S., MD

Memory Center, Bagatelle Hospital, Talence, France

P140 - Item bias in the measurement of functional impairment: a cross-cultural comparability study in eight international cognitive aging studies

Sietske A. M. Sikkes, PhD[1,2], Mark A. Dubbelman, MSc[1], Merike Verrijp, MSc[1], Gonzalo Sánchez Benavides, PhD[3], David Facal, PhD[5], Bruno Dubois, MD, PhD[4], Wiesje M. van der Flier, PhD[1,2], Hanna Jokinen, PhD[6], Cristina Lojo-Seoane[5], José Luís Molinuevo, MD, PhD[3], Arturo X. Pereiro Rozas, PhD[5], Craig Ritchie, MD, PhD[7], Magdalini Tsolaki, MD, PhD[8,9], Ya-Huei Wu, PhD[10], Stelios Zygouris, MSc[8,11], Stephane Epelbaum, MD, PhD[4], Philip Scheltens, MD, PhD[1]

[1]Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, the Netherlands, [2]Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, [3]BarcelonaBeta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain, [4]Hôpital Pitié-Salpêtrière, IM2A, PARIS, France, [5]Department of Developmental Psychology, University of Santiago de Compostela, Spain, [6]Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Finland, [7]University of Edinburgh, United Kingdom, [8]1st Department of Neurology, Aristotle University of Thessaloniki, Greece, [9]Greek Association of Alzheimer's Disease and Related Disorders, Greece, [10]Broca Hopital, Paris, France 11 Network Aging Research, University of Heidelberg, Germany

P141 - Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer's Disease (AD): Responder Analyses of Cognitive and Functional Outcomes

Susan Abushakra MD*[1], Bruno Vellas MD[2], Serge Gauthier MD[3] , Anton Porsteinsson MD[4], Carl Sadowsky MD[5], Aidan Power MD[1], Larry Shen PhD[6], Lu Wang MS[6], Tim Lin MS[6], John Hey PhD[1], Martin Tolar MD PhD[1]

*[1]*Alzheon, Inc., Framingham, MA, USA, [2]University of Toulouse, Toulouse, France, [3]McGill University, Montreal, Canada, [4]University of Rochester, Rochester, New York, [5]Palm Beach Neurology and Nova SE University, Fort Lauderdale, Florida, [6]Pharmapace, Inc., San Diego, CA*

P142 - Exploring Genetic Associations of Alzheimer's Disease Loci with Mild Cognitive Impairment Neurocognitive Endophenotypes. Impact on cognitive and functional endpoints

Ana Espinosa, PhD[1], Begoña Hernández-Olasagarre, PhD[1], Sonia Moreno-Grau, MSc[1], Luca Kleineidam, MSc[2,3,4], Stefanie Heilmann, PhD[5,6], Isabel Hernández, MD, PhD[1], Steffen Wolfsgruber, Dipl.-Psych.[2,7], Holger Wagner, MSc[7], Maitée Rosende-Roca, MD[1], Ana Mauleón, MD[1], Liliana Vargas, MD[1], Asunción Lafuente, MD[1], Octavio Rodríguez-Gómez, MD[1], Carla Abdelnour, MD[1], Silvia Gil, MD, PhD[1], Marta Marquié, MD, PhD[1], Miguel A. Santos-Santos, MD, PhD[1], Ángela Sanabria, PhD[1], Gemma Ortega, PhD[1], Gemma Monté, PhD[1], Alba Pérez, MSc[1], Marta Ibarria, MSc[1], Susana Ruiz, MSc[1], Johannes Kornhuber, MD, PhD[8], Oliver Peters, MD[9], Lutz Frölich, MD, PhD[10], Michael Hüll, MD[11], Jens Wiltfang, MD[12], Martin Scherer, MD[13], Tobias Luck, Dipl.-Psych.[14], Steffi Riedel-Heller, MD[14], Laura Montrreal, MSc[1], Pilar Cañabate, PhD[1], Mariola Moreno, MSc[1], Silvia Preckler, MSc[1], Nuria Aguilera, MSc[1], Itziar de Rojas, MSc[1], Adela Orellana, PhD[1], Montserrat Alegret, PhD[1], Sergi Valero, PhD[1], Markus M Nöthen, MD[2,3], Michael Wagner, PhD[4,5], Frank Jessen, PhD[4,5,7], Wolfgang Maier, MD[4,5], Lluis Tárraga, MSc[1], Mercè Boada, MD, PhD[1], Alfredo Ramírez, MD, PhD[2,3,4,5] and Agustín Ruiz, MD, PhD[1]*

[1]Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain, [2]German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, [3]Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, German, [4]Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany, [5]Institute of Human Genetics, University of Bonn, Bonn, Germany, [6]Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany, [7]Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany, [8]Department of Psychiatry and Psychotherapy, University Clinic Erlangen, Erlangen, Germany, [9]Department of Psychiatry, Charité University Medicine, Berlin, Germany, [10]Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, [11]Center for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Freiburg, Germany, [12]Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany, [13]Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, [14]Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany

P143 - Baseline characterization of the European prevention of Alzheimer's dementia (EPAD) longitudinal cohort study (LCS)

Michael T. Ropacki, PhD[1], John Harrison, PhD[2,3], Joel Kramer, PsyD[3], Christopher Randolph, PhD[4], Jeffrey Kaye, MD[5], Bruce Albala, PhD[6], Karen Ritchie, PhD[7,8,9]

[1]Strategic Global Research & Development, Half Moon Bay, USA, [2]Metis Cognition Ltd, UK, [3]Alzheimer Center VUmc, Amsterdam, Netherlands, [4]Department of Neurology Memory and Aging Center, University of California at San Francisco, San Francisco, USA, [5]Department of Neurology, Loyola University Medical Center, Maywood, USA, [6]Neurology and Biomedical Engineering, Oregon Health and Science University, Portland, USA, [7]Institut National de la Santé et de la Recherche Médicale, UI061 Neuropsychiatrie, Montpellier, France, [8]Faculty of Medicine, University of Montpellier, Montpellier, France, [9]Center for Dementia Prevention, University of Edinburgh, Edinburgh, UK

P144 - Two distinct modelling approaches of cognitive decline and time to diagnosis of MCI/dementia to inform study design and to improve risk prediction in preclinical Alzheimer´s Disease

Angelika Caputo, PhD[1], Ana Graf, MD[1], Cristina Lopez Lopez, PhD, MD[1], Valery Risson, PhD[1], Giulia Lestini, PhD[1], Neva Coello, PhD[1], Amy Racine, PhD[1], Ines Paule, PhD[1], Luyuan Qi, PhD[2], Helene Karcher, PhD[3]

[1]Novartis Pharma AG, Basel, Switzerland, [2]Analytica Laser, a Certara company, Paris, France, [3]Analytica Laser, a Certara company, London, UK

P146 - Comparison of sleep measurements from actigraphy to self-reported sleep diaries

Kirsi Kinnunen PhD[1], Richard Joules, PhD[1], Janet Munro, MPhil1, Iain Simpson PhD[1], Robin Wolz, PhD[1,2], Yves Dauvilliers, MD PhD[3]

[1]IXICO Plc, London, UK, [2]Imperial College London, London, UK, [3]Sleep Unit, Department Neurology, Centre Hospitalier Universitaire, Montpellier, INSERM 1061, France

P147 - Using DCTclock's clinically-interpretable artificial intelligence for differentiating cognitively healthy subjects from amnestic Mild Cognitive Impairment and probable Alzheimer's Disease

William Souillard-Mandar[1], Braydon Schaible[1], Randall Davis PhD[1,2], Rhoda Au PhD[3], Dana Penney PhD[1,4]

[1]Digital Cognition Technologies, Inc., Waltham, MA, USA, [2]MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA, [3]Boston University Schools of Medicine and Public Health, Boston, MA, USA, [4]Lahey Hospital and Medical Center, Burlington, MA, USA

P148 - Advancing Clinical and Biomarker Research in AD: The LEAD Study

Liana G. Apostolova, MD, Paul Aisen, MD, Ani Eloyan, PhD, Anne Fagan, PhD, Tatiana Foroud, PhD, Constantine Gatsonis, PhD, Clifford Jack, MD, Joel Kramer, PsyD, Robert Koeppe, PhD, Andrew Saykin, PsyD, Arthur Toga, PhD, Prashanthi Vemuri, PhD, Gregory Day, MD, MSc, Neill Graff-Radford, MD, Lawrence Honig, MD, David Jones, MD, Sterling Johnson, PhD, Joseph Masdeau, MD, Mario Mendez, MD, Chiadi Onyike, MD, Emily Rogalski, PhD, Steve Salloway, MD, David Wolk, MD, Thomas Wingo, MD, Maria Carrillo, PhD, Brad Dickerson, MD, Gil Rabinovici, MD

P149 - Measuring Pre-Clinical Cognitive Decline over Time: Separating and Combining Alzheimer's Specific Decline and Cognitive Decline Related to Aging in Cognitive Composite Scores

Suzanne Hendrix, PhD[1], Noel Ellison, MS[1], Jessica B. Langbaum, PhD[2], Kewei Chen, PhD[3] and David A. Bennett, MD[4]

[1]Pentara Corporation, Millcreek, UT, USA, [2]Arizona Alzheimer's Consortium, Phoenix, AZ, USA, [3]University of Arizona, Tucson, AZ, USA, [4]Rush University, Chicago, IL, USA

Late Breaking Posters

LBP41 - Effects of 2-year walnut supplementation on cognitive decline in healthy elders: The Walnuts And Healthy Aging (WAHA) study

Nina Coll-Padrós[1], Aleix Sala-Vila[2,3], Cinta Valls-Pedret[2], Mercè Serra-Mir[2,3], Montserrat Cofán[2,3], Irene Roth[2], Tania Freitas-Simoes[2], Mónica Doménech[2], Lídia Vaqué-Alcázar[4], David Bartrés-Faz[4], Sujatha Rajaram[5], Joan Sabaté[5], Emilio Ros[2,3]

[1]Alzheimer Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, [2]Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clínic, Barcelona, Spain, [3]CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain, [4]Institut de Neurociències i Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona Spain, [5]School of Public Health, Loma Linda University, Loma Linda, CA, USA

LBP42 - ADCOMS: a post-hoc analysis using data from the LipiDiDiet trial in prodromal Alzheimer's disease

Suzanne B. Hendrix, PhD[1], Hilkka Soininen, MD, PhD[2,3], Pieter Jelle Visser, PhD[4,5], Alina Solomon, MD, PhD[2,6,7], Miia Kivipelto, MD, PhD[2,6,7], Tobias Hartmann, PhD[8,9] on behalf of the LipiDiDiet clinical study group

[1]Pentara Corporation, Salt Lake City, UT, USA, [2]Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, [3]Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland, [4]Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands, [5]Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, [6]Department of Clinical Geriatrics, NVS, Karolinska Institutet, Huddinge, Sweden, [7]Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden, [8]Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany, [9]Department of Experimental Neurology, Saarland University, Homburg, Germany

LBP43 - Intraventricular Injection of Human Umbilical Cord Blood Mesenchymal Stem Cells in Patients with Alzheimer's Disease Dementia: A Phase I Clinical Trial

Hee Jin Kim, MD, PhD[1,2], Kyung Rae Cho, MD[2,3], Hyemin Jang, MD, PhD[1,2], Jung Il Lee, MD, PhD[2,3], Seongbeom Park, MS[1,2], Soo Jin Choi[4], Sung Tae Kim, MD, PhD[5], Seung Hwan Moon, MD, PhD[6], Kyung-Han Lee, MD, PhD[6], Sang Won Seo, MD, PhD[1,2,7], Duk L. Na, MD, PhD[1,2,8]

Departments of [1]Neurology, [3]Neurosurgery, [5]Radiology, and [6]Nuclear Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, [2]Neuroscience Center, Samsung Medical Center, Seoul, Korea, [4]Biomedical Research Institute, MEDIPOST Co., Ltd, Seoul, Korea, [7]Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea, [8]Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea

LBP44 - Exploratory analysis of results from the NILVAD trial suggest benefit in very mild AD subjects

Michael Mullan, MBBS, PhD[1,2], Laila Abdullah, PhD[2], Heather Langlois[2], Fiona Crawford, PhD[1,2], Anders Wallin, MD[3], Suzanne Hendrix, PhD[4], Kaj Blennow, MD, PhD[5], Brian Lawlor, MBBS[6]. The NILVAD consortium

[1]Archer Pharmaceuticals, Sarasota, FL, USA, [2]Roskamp Institute, Sarasota, FL, USA, [3]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden, [4]Pentara Corporation, Salt Lake City, UT, USA, [5]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden, [6]Trinity College Dublin, Dublin, Ireland

LBP45 - Can digital footprints capture clinically relevant gait endpoints in non-clinically setting: a Proof of Concept?

Marie Mc Carthy[1], Crystal Gon[2]

[1]ICON PLC, Dublin, Ireland, [2]Trinity College Dublin, Ireland

LBP46 - Using the power of Dementias Platform UK (DPUK) cohorts to investigate the longitudinal effects of childhood adversity on adult cognition and health outcomes: implications for cognitive change and dementia outcomes

Sarah Bauermeister, PhD and John Gallacher, PhD

University of Oxford, Department of Psychiatry, Oxford, UK

Theme 6. Cognitive assessment and clinical trials

P6 - Evaluation of titers of antibodies against peptides of subunits NR1 and NR2B of glutamate receptor by enzyme-linked immunosorbent assay in psychiatric patients with anti-thyroid antibodies

Takahiro Ikura, MD, PhD, Yokohamacity University Psychiatry

P14 - Anosognosia in Mild Cognitive Impairment and Dementia

Dong Won Yang[1], Ahro Kim1 Dong Woo Lee[2], Hyun Jeong Han[3], Jee Hyang Jeong[4], Jun Hong Lee[5], Jun-Young Lee[6], Kee Hyung Park[7], Kyung Won Park[8], SangYun Kim[9], Seong Hye Choi[10], Young Chul Youn[11]

[1]Department of Neurology, Catholic University of Korea, Seoul, Korea, [2]Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea, [3]Department of Neurology, Myongji Hospital, Goyang, [4]Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, [5]Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, [6]Department of Psychiatry and Neuroscience Research Institute, Seoul National University College of Medicine & SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, [7]Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea. Department of Neurology, [8]Cognitive Disorders and Dementia Center, Dong-A University College of Medicine, Busan, South Korea, [9]Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, [10]Department of Neurology, Inha University School of Medicine, Incheon, South Korea. Department of Neurology, [11]Chung-Ang University Hospital, Seoul, Korea

P24 - Clinical correlates of types of memory complaints in mild cognitive impairment

Seon Young Ryu, MD, PhD[1], Sang Bong Lee, MD, PhD[1], Taek Jun Lee, MD[1], Yu Jin Jung, MD, PhD[1]

[1]Neurology Department, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea

P29 - A comparison between brief episodic memory and semantic memory tasks within a screening test for mild cognitive impairment

Pamela Voccia EdS[1], Katherine Kruczek, MS[1]

[1]Bioclinica Research, The Villages, FL USA

P33 - Comparative evaluation of tests for the cognitive dysfunction screening in the national medical check-up

Ahro Kim[1], Dong Won Yang[1], Dong Woo Lee[2], Hyun Jeong Han[3], Jee Hyang Jeong[4], Jun Hong Lee[5], Jun-Young Lee[6], Kee Hyung Park[7], Kyung Won Park[8], SangYun Kim[9], Seong Hye Choi[10], Young Chul Youn[11]

[1]Department of Neurology, Seoul St. Mary's hospital, Catholic University of Korea, Seoul, Korea, [2]Department of Psychiatry, Inje University Snaggye Paik Hospital, Seoul, Korea, [3]Department of Neurology, Myongji Hospital, Goyang, [4]Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, [5]Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, [6]Department of Psychiatry, Seoul National University Boramae Hospital, Seoul, Korea, [7]Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea, [8]Department of Neurology, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health, Busan, South Korea, [9]Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, [10]Department of Neurology, Inha University School of Medicine, Incheon, South Korea, [11]Department of Neurology, Chung-Ang University Hospital, Seoul, Korea

P34 - A multicentre, pilot study to evaluate an Augmented Reality test (ALTOIDATM) for mild cognitive impairment detection

Mircea Balasa, MD, PhD[1,2], Adrià Tort-Merino, MSc[1], Ioannis Tarnanas, PhD[2,3], David Bartrés-Faz, PhD[4], Rory Boyle, MSc[5], Laura Rai MSc[5], Rob Whelan, PhD[2,5], Raquel Sanchez-Valle, MD, PhD[1]

[1]Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, Barcelona, Spain, [2]Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland, [3]Altoida AG, Lucerne, Switzerland, [4]Departament de Medicina, Faculty of Medicine and Health Sciences, University of Barcelona, [5]School of Psychology, Trinity College Dublin, Dublin, Ireland

P41 - Cognitive impairment under treatment with 2nd and 3rd generation antihistamines in elderly subjects

Georg Adler, Nadja Baumgart

Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P42 - Using Bayesian methods to model normative CANTAB cognition data across adulthood

Pasquale Dente[1], Elizabeth Baker[1], Jack Cotter[1], Francesca Cormack[1], Jennifer H Barnett[1,2]

[1]Cambridge Cognition Limited, Cambridge, UK, [2]University of Cambridge, Cambridge, UK

P47 - Predicting the course of Alzheimer's

Samuel Iddi, PhD[1,3], Dan Li, PhD[1], Wesley K Thompson, PhD[2], Michael S. Rafii, MD, PhD[1], Paul S. Aisen, MD[1], and Michael C Donohue, PhD[1]

[1]ATRI, University of Southern California, San Diego, CA, United States, [2]Department of Family Medicine and Public Health, University of California, San Diego, USA, [3]Department of Statistics, University of Ghana, Legon-Accra, Ghana

P48 - Impaired delayed recall on the International Shopping List Task predicts amyloid positivity and longitudinal decline in CDR-SB scores in MCI

Sharon Rosenzweig-Lipson, PhD[1], Richard Mohs, PhD[1], Paul Maruff, PhD[2], Michela Gallagher, PhD[1,3] and Arnold Bakker, PhD[3]

[1]Agenebio, Inc., Baltimore, MD, USA, [2]Cogstate, Ltd., Melbourne, Victoria, Australia, [3]Johns Hopkins University, Baltimore, MD, USA

P49 - MMSE screening data quality for Alzheimer's disease studies across countries

Jordan Mark Barbone, BA[1], Todd M. Solomon, PhD[1], H. Todd Feaster, PsyD[1], Macarena Garcia-Valdecasas Colell, MSc[3], David S. Miller, MD, MA[1]

[1]Bracket, Wayne, PA, USA, [2]Boston University School of Medicine, Boston, MA, USA, [3]Bracket, Reading, UK

P50 - Affective variability predicts cognitive fluctuation and decline in older adults

Edward Zamrini, MD[1], Michael Malek-Ahmadi, PhD[2], Kathy O'Connor[1], Sharon Schofield[1]
[1]Banner Sun Health Research Institute, Sun City, USA, [2]Banner Alzheimer's Institute, Phoenix, USA

P51 - Validation of the geriatric depression scale in the elderly Korean with Alzheimer's disease

Moon Ho PARK, MD, PhD, Do-Young KWON, MD, PhD
Department of Neurology, Korea University Ansan Hospital, Ansan, South Korea

P52 - Can TMT-black and white predict the white matter hyperintensity of MRI in the community based elderly?

Young Chul Youn, MD, PhD
Neurology Department, Chung-Ang University College of Medicine, Seoul, Korea

P55 - CANTAB tests predict change in global functioning in patients with amnestic mild cognitive impairment

Elizabeth Baker PhD[1], Peter Annas PhD[1], Giovanni B. Frisoni, MD, PhD[2,19], David Bartres-Faz, MD, PhD[3], Beatriz Bosch PhD[3], José Luis Molinuevo, MD, PhD[3], Mira Didic, MD, PhD[4,5], Francesca De Anna[4,5], Lucilla Parnetti, MD, PhD[6], Nicola Salvadori PhD[6], Jens Wiltfang, MD, PhD[7,15], Flavio Nobili, MD, PhD[8], Nicola Girtner, Psy.D[8], Peter Schönknecht, MD, PhD[9], Pieter J. Visser, MD, PhD[10], Paolo M. Rossini, MD, PhD[11], Paola Chiovenda, MA[11], Pierre Payoux, MD, PhD[12], Andrea Soricelli, MD, PhD[13], Marco Salvatore, PhD[13], Magda Tsolaki, MD, PhD[14], Jill C. Richardson, PhD[16], Régis Bordet, MD, PhD[17], Olivier Blin, MD, PhD[18], Gianluigi Forloni[20] on behalf of the PharmaCog Consortium

[1]Cambridge Cognition Ltd, Bottisham, Cambridge, UK, [2]Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy, [3]Department of Psychiatry and Clinical Psychobiology, Faculty of Medicine, University of Barcelona and Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, [4]Aix-Marseille Universite, INSERM, France, [5]Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France, [6]Clinica Neurologica, Universita di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy, [7]Department of Psychiatry and Psychotherapy, Faculty of Medicine, LVR-Hospital Essen, University of Duisburg-Essen, Essen, Germany, [8]Clinical Neurology, Department of Neurosciences, Rehabilitation, Ophthalmology and Maternal-Fetal Medicine, University of Genoa, Genoa, Italy, [9]Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany, [10]Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, the Netherlands, [11]Department of Gerontology, Neurosciences & Orthopedics, Catholic University, Rome, Italy, [12]ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France, [13]SDN Istituto di Ricerca Diagnostica e Nucleare, Naples, Italy, [14]Third Neurologic Clinic, Medical School, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, [15]Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August-University, Goettingen, Germany, [16]Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK, [17]University of Lille, Inserm, CHU Lille, U1171 – Degenerative and Vascular Cognitive Disorders, Lille, France, [18]Aix-Marseille University, UMR Inserm 1106, Institute Neurosciences Sytemes, Marseille, France, [19]Memory Clinic and LANVIE – Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland, [20]Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy

P63 - Validating simulated cognition trajectories based on ADNI against trajectories from the National Alzheimer's Coordinating Center (NACC) dataset

Ali Tafazzoli, PhD[1], Josh Weng, PhD[2], Kelly Sutton, PhD[3], Michal Litkiewicz, MSc[3], Ameya Chavan, BS[1], Mira Krotneva, MSc[4], Anuraag Kansal, PhD[1]
[1]Evidera, Bethesda, MD, USA, [2]Evidera, Waltham, MA, USA, [3]Evidera, London, UK, [4]Evidera, Montreal, Canada

P68 - Recruitment using the DCTclockTM

Daniel Lawler MD[1], Stephen Thein PhD[1]
[1]Pacific Research Network Inc., San Diego, CA, USA

P70 - Strategy or symptom: semantic clustering and risk of Alzheimer's disease

Jamie Ford, MSc[1], Bang Zheng, MSc, MD[1], Barbara Hurtado, M.A, CPsychol[1], Chi Udeh-Momoh, MSc, PhD[1], Geraint Price, MSc, D Clin Psy[1]
[1]Imperial College London, UK

P72 - Tau is associated with longitudinal memory decline in healthy subjects: the need for an early detection of subtle cognitive changes

Adrià Tort-Merino, MSc[1], Jaume Olives, MSc[1], María León, MSc[1], Claudia Peñaloza, PhD[2], Natalia Valech, MSc[1], Petra Grönholm-Nyman, PhD[3], Pablo Martínez-Lage, MD, PhD[4], Juan Fortea, MD, PhD[5,6], José Luis Molinuevo, MD, PhD[1,7], Raquel Sánchez-Valle, MD, PhD[1,8], Matti Laine, PhD[3], Antoni Rodríguez-Fornells, PhD[2,9,10], Lorena Rami, PhD[1,8]

[1]Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain, [2]Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain, [3]Department of Psychology, Åbo Akademi University, FIN-20500 Turku, Finland, [4]Neurología, Fundación CITA-Alzhéimer Fundazioa, Centro de Investigación y Terapias Avanzadas, San Sebastián, Guipúzcoa, España, [5]Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau and Institute of Biomedical Research, Barcelona, Spain, [6]Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas Neurodegenerativas, CIBERNED, Spain, [7]Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain, [8]August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, [9]Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain, [10]Department of Cognition, Development and Education Psychology, Campus Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain

P75 - Flunks and flukes: recognising unrepresentative performance on cognitive tests

Geraint Price, D Clin Psy[1], Bowen Su, MD[1]
[1]Imperial College London, UK

P87 - Assessing decline in visuospatial working memory associated with subjective cognitive impairment using a tablet-based measure of hippocampal-dependent learning

Alexandra S. Atkins[1], Anzalee Khan[1,2], Daniel Ulshen[1], John Harrison[3,4], Brenda L. Plassman[5], Kathleen A. Welsh-Bohmer[5] & Richard S.E. Keefe[1,6]

[1]NeuroCog Trials, Durham, NC, [2]Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, [3]Alzheimer Center, VUmc, Amsterdam, The Netherlands, [4]oPPN, King's College, London, UK, [5]Duke University Bryan ADRC, Durham, NC, [6]Duke University Medical Center, Durham, NC, [7]Duke University Medical Center, Durham, NC

P88 - Severe cognitive impairment in older adult heart failure patients: Preliminary findings from the Deus ex Machina study

Emília Moreira, Psy, MPH, PhD[1] , Sónia Martins, Psy, PhD[1,2], Luís Filipe Azevedo, MD, PHD[1,3], José SilvaCardoso, MD, PhD[1,4,5], Lia Fernandes, MD, PhD[1,2,6]

[1]Center for Health Technology and Services Research/CINTESIS, Faculty of Medicine, University of Porto, Portugal, [2]Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Portugal, [3]Department of Community Medicine, Information and Health Decision Sciences/MEDCIDS, Faculty of Medicine, University of Porto, Portugal, [4]Department of Medicine, Faculty of Medicine, University of Porto, Portugal, [5]Department of Cardiology S. João Hospital Center, Porto, Portugal, [6]Clinic of Psychiatry and Mental Health, S. João Hospital Center, Porto, Portugal

P89 - The effect of dizziness in patients with cognitive impairments

Seunghee Na, MD, In-Uk Song, MD, PhD

Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Korea, Incheon, Korea

P151 - Selection of depression-specific dementia cases with replication in two cohorts

Donald R. Royall, MD[1-4], Raymond F. Palmer, PhD[3]

[1]Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, [2]Department of Medicine, UTHSCSA, San Antonio, Texas, USA, [3]Department of Family & Community Medicine. UTHSCSA, San Antonio, Texas, USA, [4]South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P152 - Selection of depression-specific dementia cases with replication in two cohorts

Donald R. Royall, MD[1-4], Raymond F. Palmer, PhD[3]

[1]Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, [2]Department of Medicine, UTHSCSA, San Antonio, Texas, USA, [3]Department of Family & Community Medicine. UTHSCSA, San Antonio, Texas, USA, [4]South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P153 - Assessment and speech-language intervention program in Non-Fluent Primary Progressive Aphasia: A case study

Beatriz Valles-González[1] & Vicent Rosell-Clari[1,2]

[1]Speech and Language Pathology Clinic. Lluís Alcanyís Foundation-Universitat de Valencia, [2]Basic Psychology Department. Universitat de Valencia

P154 - Prediction of APOE ε4 Burden from Cognitive Assessment

Royall DR[1-4], Palmer RF[3] for the Alzheimer's Disease Neuroimaging Initiative*

[1]Departments of Psychiatry, [2]Medicine, Family & [3]Community Medicine, The University of Texas Health Science Center at San Antonio and the [4]South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC)

P155 - Could Telemedicine improve neurocognitive disorders detection and diagnosis in nursing home?

Armelle Leperre-Desplanques[1], Isabelle Hauger[2], Sylvain Gaulier[1], Antonis Politis[3], Shima Mehrabian[4], Audrey Maillet[1], Pierre Krolak-Salmon[1]

[1]Clinical and Research Memory Centre, Lyon Institute for Elderly, Hospices Civils de Lyon, Inserm UMR1028, CNRS UMR 5292, Lyon University, France, [2]Résidence Talanssa, Talence, France, [3]National and Kapodistrian University of Athens, Athens, Greece, [4]Clinic of Neurology, UH "Alexandrovska", Medical University, Sofia, Bulgaria

P156 - Cognitive Blackouts in Mild Cognitive Impairment of the Amnestic Type and mild Alzheimer's Dementia

Georg Adler, Agnies Marczak, Jana Binder, Katharina Gnosa

Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P157 - Feasability of the neuropsychological battery camcomg-ds for the detection of cognitive decline in people with down syndrome

Laura Videla[1,2,3] Bessy Benejam[1], María Carmona-Iragui[1,2,3], Susana Fernández[1], Isabel Barroeta[1,2,3], Sebastián Videla[2], Alberto Lleó[2,3], Rafael Blesa[2,3], Juan Fortea[1,2,3]

[1]Alzheimer Unit - Down, Down Medical Center, Fundació Catalana Síndrome de Down, [2]Memory Unit of the Neurology Service of the Hospital de la Santa Creu and Sant Pau, Biomedical Research Institute of Sant Pau, Universitat Autònoma de Barcelona, [3]Central Biomedical Research Center (CIBERNED)

P158 - Distinct patterns of cognitive decline between early-onset Alzheimer's disease and late-onset Alzheimer's disease

Adrià Tort Merino, MSc[1], Jaume Olives, MSc[1], Neus Falgàs, MD[1], Mircea Balasa, PhD[1], Magda Castellví, MSc[1], Sergi Borrego, MD[1], Beatriz Bosch, PhD[1], María León, MSc[1], Ana Salinero, MSc[1], Guadalupe Fernández, RN[1], Anna Antonell, PhD[1], Raquel Sánchez-Valle, MD, PhD[1], Lorena Rami, PhD[1], Albert Lladó, MD, PhD[1]

[1]Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain

P159 - High level of plasmatic amyloid Aβ 1-40 increase the risk of cognitive decline in 3C study with 14 years of follow-up

Audrey Gabelle, MD. Ph.D[1,2,3], Laure-Anne Gutierrez, MSc[2,3], Thibault Mura M.D, Ph.D[2,3], Jean-François Dartigues, Ph.D[4,5], Olivier Rouaud, MD[6], Jean-Charles Lambert Ph.D[7,8,9,10], Catherine Helmer, Ph.D[4,5], Claudine Berr M.D, Ph.D[2,3]

[1]Memory Research and Resources Center, Montpellier University Hospital, Montpellier, [2]Inserm U1061, La Colombière Hospital, Montpellier, [3]University of Montpellier, MUSE University, Montpellier, [4]Bordeaux University, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France, [5]CHU Bordeaux, Department of Public Health, F-33000 Bordeaux, France, [6]CHRU Dijon, Centre Mémoire Ressources et Recherche, Dijon, France, [7]CHRU de Lille, Lille, France, [8]INSERM U744, Lille, France, [9]Institut Pasteur de Lille, Lille, France, [10]Université de Lille Nord de France, Lille, France

P162 - Using graphical hierarchical bayesian cognitive process models applied to common memory tests to detect ad pathology within normal subjects

William R. Shankle, MS, MD[1,2,3], Junko Hara, PhD[1,3], Jason R. Bock, MA[1], Dennis Fortier, MBA[1], Tushar Mangrola, MS[1], Michael Lee, PhD[2], Gregory E. Alexander, PhD[2], William H. Batchelder, PhD[2], Ronald C. Petersen, MD, PhD[4], Walter Kremers, PhD[4]

[1]Medical Care Corporation, Newport Beach, CA, USA, [2]Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA, [3]Pickup Family Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA, USA, [4]Mayo Clinic, Rochester, MN, USA

Late Breaking Posters

LBP47 - Strategic Memory Alzheimers Rehabilitation Training (SMART) Memory Program for Amnestic Mild Cognitive Impairment (aMCI): Reporting the Results of a Randomized Clinical Trial

John W. DenBoer, Ph.D., SMART Brain Aging, Inc

LBP48 - Memory errors of commission rather than errors of omission discern aging and early Alzheimer's disease

Matthias W. Riepe, MD, Claudia Lanza, PhD, Karolina Sejunaite, MS

Department of Psychiatry and Psychotherapy II, Mental Health & Old Age Psychiatry, Ulm University, Ulm, Germany

LBP49 - Standard cognitive assessment in the era of biomarkers and disease-modifiers

Marina Boccardi, PsyD, PhD[1,2], Stefano Cappa, MD, PhD[2], Bruno Dubois, MD[3], Jean Georges[4], Matthias Kliegel, PsyD, PhD[5], Bengt Winblad, MD, PhD[6], David Salmon, PhD[7], Giovanni Frisoni, MD[1,2], Andreas Monsch, PsyD, PhD[8], for the Task Force for Harmonizing Neuropsychological Assessment for Dementing Neurodegenerative Disorders

[1]LANVIE, Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland, [2]IRCCS S.Giovanni di Dio, Fatebenefratelli, Brescia, Italy, [3]Dementia Research Center, Hôpital Pitié-Salpêtrière, Paris, France, [4]Alzheimer Europe, [5]Laboratory of Cognitive Aging, University of Geneva, Geneva, Switzerland, [6]Karolinska University Hospital, Stockholm, Sweden, [7]Department of Neurosciences, University of California San Diego School of Medicine, United States, [8]University of Basel, Basel, Switzerland

LBP50 - Lanabecestat: Rater performance and error characteristics of efficacy assessments in the DAYBREAK-ALZ study

Alette M. Wessels, PhD[1], Jordan Mark Barbone, BA[2], Danielle T. DiGregorio, PsyD[2], David S. Miller, MD, MA[2], Jamie A. Mullen, MD[3], & John R. Sims, MD[1]

[1]Eli Lilly and Company, Indianapolis, IN, USA, [2]Bracket, Wayne, PA, USA, [3]AstraZeneca Pharmaceuticals, Cambridge, MA, USA

LBP51 - iPSC model of CHRFAM7A effect on a7 nicotinic acetylcholine receptor function may explain the translational gap in drug development

Ivanna Ihnatovych[1], Tapan Nayak[1], Aya Ouf[1], Norbert Sule[2], Barbara Birkaya[1], Lee Chaves[1], Anthony Auerbach[1]

[1]SUNY at Buffalo, [2]Roswell Park Cancer Institute

LBP52 - Effects of Age and CSF measures of Tau on Mnemonic Discrimination of Objects and Scenes in Medial Temporal Lobe Pathways

David Berron, PhD[1,2,3], Arturo Cardenas-Blanco, PhD[4], Daniel Bittner, MD[2], Coraline D. Metzger, MD, PhD[5], Annika Spottke, MD[6,7], Michael Heneka, MD[7,8], Klaus Fließbach, MD[9,10], Anja Schneider, MD[7,8], Stefan J. Teipel, PhD, MD[11,12], Michael Wagner, PhD[7,13], Oliver Speck, Prof. Dr.[14], Frank Jessen, MD, Prof.[7,15], Emrah Düzel, MD[4,5] and the DELCODE study group

[1]Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden, [2]University Hospital Magdeburg, Magdeburg, Germany, [3]German Center for Neurodegenerative Diseases, Magdeburg, Germany, [4]German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany, [5]Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany, [6]Department of Neurology, University Hospital of Bonn, Bonn, Germany, [7]German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, [8]Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany, [9]DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany, [10]Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany, [11]Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany, [12]German Center for Neurodegenerative Diseases, Rostock, Germany, [13]Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital, Bonn, Germany, [14]Department of Biomedical Magnetic Resonance, Otto-von-Guericke University, Magdeburg, Germany, [15]Department of Psychiatry, University Hospital Cologne, Cologne, Germany

Theme 7. Behavioral disorders and clinical trials

P32 - Effect of memantine on behavioral and psychological symptoms of dementia (BPSD) of Alzheimer's disease - Study of changes in cerebral blood flow by spect imagingAims

Kiyoshi Kanaya[1], Shine Abe[2]

[1]MD, Geriatric medicine, Tokyo Medical University Hachioji medical center, [2]MD, Geriatric medicine, Tokyo Medical University Hachioji medical center

P37 - Clusterization of behavioral and psychological symptoms of dementia (BPSD)

Timofey L. Galankin, MD, PhD[2], Anton Y. Bespalov, MD, PhD[1,2], Hans J. Moebius, MD, PhD[1]

[1]EXCIVA, Am, Germany, [2]Valdman Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia

P43 - The effect of dizziness in patients with cognitive impairments

Seunghee Na, MD, In-Uk Song, MD, PhD

Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Korea, Incheon, Korea

P163 - A multicenter, randomized trial to assess efficacy of Therapeutic Intervention Program for Dementia Caregivers (I-CARE)

Jihye Hwang, MD, PhD[2], Geon-Ha Kim, MD, PhD[3], Hae-Ri Na, MD, PhD[4], Soo-Jin Cho, MD, PhD[5], Kyung-Ho Yu, MD, PhD[6], Do Hoon Kim, MD, PhD[7], Jae-Hong Lee, MD, PhD[8], Seong-Hye Choi, MD, PhD[9]

[2]Department of Neurology, Keimyung University School of Medicine, [3]Department of Neurology, Ewha Womans University School of Medicine, [4]Department of Neurology, Bobath Memorial Hospital, [5,6,7]Hallym University School of Medicine, [8]University of Ulsan College of Medicine, Department of Neurology, [9]Inha University School of Medicine

Late Breaking Posters

LBP53 - Prevalence of obstructive sleep apnea in Alzheimer's disease patients

Anna Carnes, PhD[1], Carme Jorge[1], MD, Benítez ID[2,3], Faride Dakterzada[1], Olga Minguez[2], Raquel Huerto[1], Montse Pujol[2], MD, PhD, Anna Gaeta, MD[2], Alfonso Arias[1], MD, Aurora Gibert[1], Manuel Sanchez de la Torres[2,3], MD, PhD, Ferran Barbé[2,3], MD, PhD, Gerard Piñol-Ripoll[1], MD, PhD

[1]Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria Lleida (Spain), [2]Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain, [3]Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

Theme 8. Health economics and clinical trials

P17 - Effect of physical activity on the progression of Alzheimer's disease: the CREDOS study

Seong Hye Choi[1], Jee Hyang Jeong[2], Eun-Joo Kim[3], Kyung Won Park[4], Bora Yoon[5], Soo Jin Yoon[6], Yang-Ki Minn[7], Young Ju Suh[8]

[1]Department of Neurology, Inha University School of Medicine, Incheon, South Korea, [2]Department of Neurology, Ewha Womans University School of Medicine, Seoul, South Korea, [3]Department of Neurology, Pusan National University School of Medicine, Busan, South Korea, [4]Department of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan, South Korea, [5]Department of Neurology, College of Medicine, Konyang University, Daejeon, South Korea, [6]Department of Neurology, Eulji University School of Medicine, Daejeon, South Korea, [7]Department of Neurology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea, [8]Department of Biomedical Sciences, Inha University School of Medicine, Incheon, South Korea

P40 - The Survey for Current State and Dognition of Activities of Daily Living in Korean dementia patients

Kee Hyung Park, MD, PhD[1], Chan-Nyoung Lee, MD, PhD[2], Hojin Choi, MD, PhD[3]

[1]Department of Neurology , Gachon University, Gil Medical Center, Incheon, Korea, [2]Department of Neurology, Korea University College of Medicine, Seoul, Korea, [3]Department of Neurology, Hanyang University Guri Hospital, Guri, Korea

P58 - Young onset diseases care pathways. Parcours des malades Alzheimer et apparentés jeunes - PARMAAJ

Adeline Rollin-Sillaire, MD[1,2], Brigitte Leprince[3], Catherine Adnet-Bonte, MD[3], Laetitia Breuilh, PhD[2], Florence Pasquier, MD, PhD[1,2]

[1]Centre National de Référence des Malades Alzheimer Jeunes, Neurology Department, Centre Hospitalier Universitaire de Lille, France, [2]Excellence Laboratory DISTALZ, Inserm U1171, Univ Lille, [3]Meotis, Centre Hospitalier Universitaire de Lille, France

P164 - Dutch online registry for recruitment of participants for dementia studies

Marissa D. Zwan, PhD[1], Derek Flenniken[2,3], Shannon Finley, MA[2], Aaron Ulbricht[2,3] ,Rachel Nosheny, PhD[2,3], Wiesje M. van der Flier, PhD[1], Philip Scheltens, MD, PhD[1], Diana Truran-Sacrey[2], Michael W. Weiner, MD[2,3], Niels D. Prins, MD, PhD[1]

[1]Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands, [2]Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran's Administration Medical Center, San Francisco, USA, [3]UCSF Department of Radiology and Biomedical Imaging, San Francisco, USA

Theme 9. Epidemiology and clinical trials

P17 - Awareness of Alzheimer's dementia as their own disease in Asian Countries

San Jung, YongSoo Shim, SangYun Kim

Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, College of Medicine, The Catholic University of Korea, Bucheon St. Mary's Hospital, Seoul, Korea, Department of Neurology, Seoul National University College of Medicine & Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seoul, Korea

P38 - Subjective memory complaints are related to the social participation and leisure activities: TOyoake Integrated Care Study (TOICS)

Hajime Takechi, MD, PhD[1], Akira Tsuzuki, RPT, DMSc[2], Komaki Matsumoto, Ms[3], Hiroyuki Nishiyama, Mr[4], Masatoshi Ogawa, Mr[3], Yoshikiyo Kanada, RPT, DMSc[2]

[1]Department of Geriatrics and Cognitive Disorders, School of Medicine, Fujita Health University, Aichi, Japan, [2]Faculty of rehabilitation, School of Health Science, Fujita Health University, Aichi, Japan, [3]Department of community care, Toyoake city municipal] office, Aichi, Japan, [4]Gyosei Corporation, Tokyo, Japan

P46 - Alzheimer's disease drug development pipeline: 2018

Jeffrey Cummings, MD, ScD[1], Garam Lee, PharmD[1], Aaron Ritter, MD[1], Kate Zhong, MD[2]

[1]Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, [2]Global Alzheimer Platform, Washington, D.C., USA

P165 - Association between amyloid status and multiple chronic diseases in European Prevention of Alzheimer's Dementia (EPAD): network and cluster analyses

Lucy E Stirland, MBChB, MRCPsych[1], Tom C Russ MBChB, PhD, MRCPsych[1,2], Graciela Muniz Terrera, PhD[1], Craig W Ritchie MBChB, PhD, MRCPsych[1]

[1]Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK, [2]Alzheimer Scotland Dementia Research Centre, Edinburgh, UK

P166 - Concord-AD: An International Network of Cohorts for Better Understanding Alzheimer's Disease

Samantha C Burnham, PhD[1], Preciosa M Coloma, MD, PhD[2], Teresa J. Christainson[3], BS, Jean-François Dartigues, MD, PhD[4,5], Rachelle Doody, MD, PhD[6], Oskar Hansson, MD, PhD[7], Catherine Helmer, MD, PhD[4,8], Joseph S Kass, MD, JD[9], Colin L Masters, MD[10], Sebastian Palmqvist, MD, PhD[7,11], Valory N Pavlik, PhD[9], Ronald C. Petersen, MD, PhD[3,12], Rosebud O. Roberts, MB ChB, MS[3,12], Maria Vassilaki, MD, MPH, PhD[3], Barbara Schauble[13] and Mary Sano, Ph.D.[14,15]

[1]eHealth, CSIRO Health & Biosecurity, Melbourne, Australia, [2]Product Development Personalised Health Care, Data Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland, [3]Department of Neurology, Mayo Clinic, Rochester, MN, USA, [4]Bordeaux University, Bordeaux, France, [5]INSERM, ISPED, Centre INSERM U897-Epidémiologie-Biostatistique, Bordeaux, France, [6]F. Hoffmann-La Roche Ltd, Basel, Switzerland, [7]Clinical Memory Research Unit, Lund University, Malmö, Sweden, (8)INSERM U897, BORDEAUX, France, [9]Baylor College of Medicine, Houston, TX, USA, [10]The Florey Institute of Neuroscience and Mental Health, Parkville, Australia, [11]Department of Neurology, Skåne University Hospital, Lund, Sweden, [12]Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA, [13]Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland, [14]Department of Psychiatry, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA, [15]James J. Peters VA Medical Center, Bronx, NY, USA

P167 - Cognitive and brain structural correlates of insomnia symptoms in middle-aged healthy adults

Oriol Grau-Rivera[1], Juan Domingo Gispert[1,2], Grégory Operto[1], Carles Falcón[1,2], Raffaele Cacciaglia[1], Gonzalo Sánchez-Benavides[1], Anna Bugulat[1], Nina Gramunt[1,3], Gemma Salvadó[1], Marc Suárez-Calvet[1], Carolina Minguillón[1], Karine Fauria[1], José Luis Molinuevo[1,3,4]

[1]Barcelonaβeta Brain Research Center, Catalonia, Spain, [2]Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, Spain, [3]CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain, [4]Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain

P168 - A Phase II randomized clinical trial of high-dose versus standard-dose Vitamin D3 in an ethnically diverse sample of older adults

John Olichney, MD[1], Charlie DeCarli, MD[1], Joshua W Miller, PhD[2], David Johnson, PhD[1], Sarah Tomaszewski-Farias, PhD[1], Bruce Hammock, PhD[3], Brittany Dugger, PhD[4], Lee-Way Jin, MD, PhD[4], Mary McPhail-Ciufo, DO[1], Robert Soohoo, BS[5], Dan Mungas, PhD[1], Danielle Harvey, PhD[6]

[1]Neurology Department, University of California Davis, Sacramento, CA, USA, [2]Department of Nutritional Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, [3]Department of Entomology & Comprehensive Cancer Center, University of California Davis, Davis, CA, USA, [4]Pathology Department, University of California Davis, Sacramento, CA, USA, [5]Psychology Department, University of California Davis, Davis, CA, USA, [6]Department of Public Health Sciences, University of California Davis, Davis, CA, USA

Late Breaking Posters

LBP54 - Psychometric methodologies to increase scale-reliability in dementia-focused epidemiology: Outcomes from the European Prevention of Alzheimer's Disease Study and UK Biobank

Sarah Bauermeister, PhD and John Gallacher, PhD

University of Oxford, Department of Psychiatry, Oxford, UK

LBP55 - STOPBANG and Berlin Questionnaire as screening tools to identify obstructive sleep apnea in Alzheimer's disease

Anna Carnes, PhD[1], Benítez ID[2,3], Faride Dakterzada[1], Olga Minguez[2], Raquel Huerto[1], Montse Pujol[2], MD, PhD, Anna Gaeta, MD[2], Alfonso Arias[1], MD, Aurora Gibert[1], Manuel Sanchez de la Torres[2,3], MD, PhD, Ferran Barbé[2,3], MD, PhD, Gerard Piñol-Ripoll[1], MD, PhD

[1]Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain, [2]Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain, [3]Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

LBP56 - Exposure to benzodiazepines and development of Alzheimer's disease: a cohort study in a Health Region of Catalonia between 2002 and 2015

Carnes A[1], Torres-Bondia, F[1], de Batlle J[2], Piñol-Ripoll, G[1]

[1]Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria Lleida, Spain, [2]Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain

Theme 10. Animal model and clinical trials

P102 - Concussive head injury exacerbates Alzheimer's disease brain pathology. Superior neuroprotection by Co-administration of TiO2 nanowired Cerebrolysin together with antibodies to neuronal nitric oxide synthase and mesenchymal stem cells

Hari Shanker Sharma[1]*, José V Lafuente[2], Dafin F Muresanu[3a], Rudy J Castellani4, Mark A Smith[5], Ala Nozari[6], Ranjana Patnaik[7], Z Ryan Tian[8], Asya Ozkizilcik[9], Stephen D Skaper[10], Herbert Mössler[11a], Aruna Sharma[1]

[1]International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, [2]Dept of Neurosciences, University of Basque Country, Bilbao, Spain, [3]Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, [a]"RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, [4]University of Maryland, Dept. of Pathology, Baltimore, MD, USA, [5]Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA 6Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, [7]School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India, [8]Dept. Chemistry & Biochemistry & [9]Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, [10]Department of Pharmacology and Anesthesiology, University of Padua, Faculty of Medicine, Padua, Italy, [11]Ever NeuroPharma, Oberburgau, Austria

P103 - Sleep deprivation aggravates Alzheimer's disease brain pathology. Enhanced neuroprotection by nanowired delivery of cerebrolysin with alpha melanocyte stimulating hormone and antibodies to alpha-synuclein

Aruna Sharma[1]*, José V Lafuente[2], Dafin F Muresanu[3a], Rudy J Castellani[4], Mark A Smith[5], Ala Nozari[6], Ranjana Patnaik[7], Z Ryan Tian[8], Asya Ozkizilcik[9], Herbert Mössler[10], Hari S Sharma[1]

[1]International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, [2]Dept of Neurosciences, University of Basque Country, Bilbao, Spain, [3]Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, [a]"RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, [4]University of Maryland, Dept. of Pathology, Baltimore, MD, USA, [5]Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, [6]Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, [7]School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India, [8]Dept. Chemistry & Biochemistry &, [9]Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, [10]Ever NeuroPharma, Oberburgau, Austria

P104 - The effect of crenezumab on beta-amyloid toxicity–induced synapse loss, neurofibrillary tangles and cell death in human neurons in vitro

Ben Chih, PhD, Reina A. Bassil, BS, Shirley Ng, BS, Maureen Beresini, PhD

Genentech, Inc., South San Francisco, CA, US

Late Breaking Posters

LBP58 - Disease modifying therapy by targeting generic protein secondary structure of pathological oligomers at any stages of Alzheimer's Disease models

Fernando Goni, PhD[1], Krystal Herline, PhD[1], Mitchell Marta-Ariza, MSc[1], Frances Prelli, MSc[1] and Thomas Wisniewski, MD[1]

[1]New York University School of Medicine, New York, USA

Theme 11. New therapies and clinical trials

P5 - Therapeutic monitoring and prediction of the effectiveness of neurotrophic therapy in patients with mild cognitive impairment of the amnestic type

Gavrilova S.[2], Volpina O.[1], Kolykhalov I.[2], Ponomareva E.[2], Selezneva N.[2], Fedorova Y. B., Karaev D.[1], A. V. Kamynin

[1]Mental Health Research Center, Moscow, Russia, [2]Institute of bioorganic chemistry M.M.Shemyakin and Y.A.Ovchinnikov Russian Academy of Sciences, Moscow, Russia

P11 - 11β-hydroxysteroid dehydrogenase type 1 inhibitors pharmacological mechanism of potential therapeutic uses- a systematic review

Sarah Gregory[1], John W. Ketelbey[2], Tamara Miller[2], Vincent S Ruffles[2], Craig W. Ritchie[1]

[1]University of Edinburgh, Edinburgh, UK, [2]Actinogen Medical Ltd, Sydney, New South Wales, Australia

P20 - SUVN-502 - Baseline characteristics of phase 2a study in moderate Alzheimer's disease - First-in-class Triple combination of SUVN-502+Donepezil+Memantine - A Promising new approach for the symptomatic treatment of Alzheimers Disease

Ramakrishna Nirogi, PhD[1], Jyothsna Ravula, MS[1], Satish Jetta, MS[1], Koteshwara Mudigonda, PhD[1], Vinod Kumar Goyal, MS[1], Santosh Kumar Pandey, MS[1], Gopinadh Bhyrapuneni, PhD[1], Renny Abraham, PhD[1], Vijay Benade, MS[1], Pradeep Jayarajan, PhD[1], Anil Shinde, PhD[1], John Ieni, PhD[1] and Venkat Jasti, MS[1]

[1]Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

P23 - Efficacy and safety of trigriluzole (BHV-4157) in patients with mild to moderate Alzheimer's dementia: T2 PROTECT AD phase 2 study design

Irfan A. Qureshi, M.D.[1], Karen Messer, Ph.D.[2], Kirsten Erickson, Ph.D.[2], Robert M. Berman, M.D.[1], Carolyn Revta[2], Tilman Oltersdorf, M.D.[2], Branko Huisa, M.D.[2], Diane Jacobs, Ph.D.[2], David Salmon, Ph.D.[2], Doug Galasko, M.D.[2], Thomas O. Obisesan, M.D.3, Neelum Aggarwal, M.D.[4], Jacobo Mintzer, M.D.[5], Judith Heidebrink, M.D.[6], Amanda Smith, M.D.[7], Miranda N. Reed, Ph.D.[8], Holly C. Hunsberger, Ph.D.[8], Lia Donahue[1], Kimberly Gentile[1], David A. Stock, Ph.D.[1], Vladimir Coric, M.D.[1], Howard Feldman, M.D.[2]

[1]Biohaven Pharmaceuticals, Inc., New Haven, CT, USA, [2]Alzheimer's Disease Cooperative Study, University of California at San Diego, La Jolla, CA, USA, [3]Howard University, Washington, DC USA, [4]Rush University Medical Center, Chicago, IL, USA, [5]Roper St. Francis Hospital, Charleston, SC, USA, [6]University of Michigan, Ann Arbor, MI, USA, [7]University of South Florida Health Byrd Alzheimer Institute, Tampa, FL, USA, [8]Auburn University, Auburn, AL, USA

P56 - Gamma-secretase modulation has multiple anti-amyloidogenic effects in vivo

Bengt Winblad[4,6], Gunnar Nordvall[1,2,3,4], Ping Yan[5], Johan Lundkvist[1,2,3,4], Johan Sandin[1,2,3,4], Henrik Biverstål[4], Henrik Zetterberg[7], Rebecka Klintenberg[3], Mats Ferm[3], John R Cirrito[5], Jin-Moo Lee[5]

[1]AlzeCure Pharma AB, Drug Discovery & Development, Huddinge, Sweden, [2]AlzeCure Foundation, Preclinical Research, Huddinge, Sweden, [3]AstraZeneca R&D, CNS & Pain iMed, Södertälje, Sweden, [4]Karolinska Institutet, Dept NVS, Div of Neurogeriatrics, Solna, Sweden, [5]Washington University School of Medicine, Dept of Neurology, St Louis, USA, [6]Karolinska University Hospital, Geriatric Clinical Trial Unit, Huddinge, Sweden, [7]Sahlgrenska University Hospital, Clinical Neurochemistry Laboratory, Mölndal, Sweden

P60 - Discovery of novel molecular chaperone modulators for the treatment of tau pathogenesis in Alzheimer's disease

Rajnish Kumar, PhD[1], Pavel Pavlov, PhD[1], Bengt Winblad, MD, PhD[1,2]

[1]Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden, [2]Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

P79 - CogniXtra preventive treatment affords neuroprotection against amyloid beta 25-35 peptide-induced toxicity in mice

Francois J. Roman[1], PhD, Johann Meunier[1], PhD, Laura Ceolin[1], PhD, Jean-Marie Butterlin[2], MS, Guillaume Blivet[3], MS, Jacques Touchon[4], MD, PhD

[1]Amylgen, Montferrier-sur-Lez, France, [2]Health Optimization Devices B.V., Maastricht, Netherlands, www.cognixtra.com, [3]Montpellier, France, [4]INSERM U1061 & Montpellier University, Montpellier, France

P84 - Clinical Development of AXS-05 (Dextromethorphan/Bupropion) for Agitation Associated with Alzheimer's Disease

Herriot Tabuteau, MD[1], Amanda Jones, PharmD[1], Cedric O'Gorman, MD[1]

[1]Axsome Therapeutics Inc., USA

P85 - Pharmacokinetics and safety profile of intravenous administration of Allopregnanolone in patients with early Alzheimer's disease

Gerson D. Hernandez, MD, MPH[1], Naoko Kono, MPH[2], Claudia M. Lopez, BS[1], Ron Irwin, PhD[3], Kathleen Rodgers, PhD[1], Jimmy Wu, PhD[4], Rosario Mollo, PhD[4], Sonia Pawluczyk, MD[5], Meng Law, MD[6], Wendy Mack, PhD[2], Lon Schneider, MD, MS[5], Roberta D. Brinton, PhD[1]

[1]Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA, [2]Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, [3]School of Pharmacy, University of Southern California, Los Angeles, CA, USA, [4]TOMO Pharmacometrics, LLC, San Mateo, USA, [5]Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, [6]Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA

P105 - SMO7883, a novel DYRK1A inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer's disease

Benoît Melchior, PhD[1], Carolyn Lai[1], Karen Duong-Polk[1], Amanda Tjitro[1], Lauren Pitzer[1], Joshua Stewart[1], Luis Dellamary[1], Scott Anderson[1], Brian Hofilena[1], Chiao-Wen Chen, PhD[1], Charlene Barroga, PhD[1], Gopi Mittapalli, PhD[1], Sunil KC, PhD[1], Philippe Marchand, PhD[1], and Yusuf Yazici, MD[1]

Samumed, LLC, San Diego, USA

P106 - Apabetalone, a BET bromodomain inhibitor, suppresses inflammatory mediators in microglia and vascular endothelial cells that contribute to neurodegenerative disease

Ewelina Kulikowski[1], Emily Daze[1], Sylwia Wasiak[1], Dean Gilham[1], Laura M. Tsujikawa[1], Brooke Rakai[1], Stephanie C. Stotz[1], Christopher Halliday[1], Ravi Jahagirdar[1], Norman C. W. Wong[1], Michael Sweeney[2] and Jan O. Johansson[2]

[1]Resverlogix Corp, Calgary, AB, Canada, [2]Resverlogix Inc, San Francisco, CA, USA

P107 - Clinico-radiological recovery of ARIA-like events in corticosteroid-treated CAA-ri patients: implications for the management of ARIA side effects of anti-amyloid immunotherapy

Fabrizio Piazza, PhD[1,2,3,4], on behalf of The iCAβ International Network Collaborators and The CAA Study Group of the Italian Society of Neurology for dementia* Jacopo C. DiFrancesco[1,2,3], Marialuisa Zedde[1,5], Federica Angiulli[1,3], Rosario Pascarella[5], Roberto Marconi[6], Francesco Perini[7], Alberto Villarejo-Galende[8], Mario Cirillo[9], Berardino Orlandi[10], Ihara Masafumi[11], Mehdi Touat[12], Hagiwara Yuta[16], Juan F. Vázquez-Costa[14], Massimo Caulo[15], Shima Atsushi[16], Alessia Giossi[17], Ricardo Nitrini[18], Massimo Musicco[2,4] *Main Network Collaborators :

[1]The inflammatory cerebral amyloid angiopathy and Alzheimer's disease βiomarkers (iCAβ) International Network, University of Milano Bicocca, Monza, Italy, [2]The CAA Study Group of the Italian Society of Neurology for dementia (SINdem), Italy, [3]University of Milano Bicocca, Monza, Italy, [4]National Research Council, Segrate, Italy, [5]Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, [6]Department of Neuroscience, Ospedale Misericordia, Grosseto, Italy, [7]St. Bortolo Hospital, Vicenza, Italy, [8]Hospital 12 de Octubre. CIBERNED, Madrid, Spain, [9]Università della Campania «L. Vanvitelli», Seconda Università degli Studi di Napoli, Italy, [10]S.S. Filippo and Nicola Hospital in Avezzano, L'Aquila, Italy, [11]National Cerebral and Cardiovascular Center, Osaka, Japan, [12]Dana-Farber Brigham and Women's Hospital, Boston, Massachusetts, Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, Paris, France & USA, [13]St. Marianna University School of Medicine, Japan, [14]Instituto de Investigación Sanitaria la Fe (IIS La Fe), Valencia, Spain, [15]University «G. d'Annunzio», Chieti, Italy, [16]Kyoto University Graduate School of Medicine. Kyoto, Japan, [17]O.U. of Neurology, ASST Cremona, Italy, [18]University of São Paulo School of Medicine, São Paulo, Brazil

P108 - Clinical Pharmacokinetics and Pharmacodynamics Demonstrate Once-Weekly CorplexTM Donepezil Transdermal System as a Therapeutic Alternative to Daily Oral Aricept

Bobby Singh, Corium International, Inc., 235 Constitution Drive, Menlo Park, California, USA

Late Breaking Posters

LBP59 - Triple therapy with SUVN-502, a 5-HT6 antagonist, donepezil and memantine in moderate alzheimer's disease: Baseline patient characteristics in phase-2a study

Alireza Atri, MD, PhD[1,2], Jeffrey L. Cummings, MD, ScD[3], John Ieni, PhD[4], Venkat Jasti, MS[4], Ramakrishna Nirogi, PhD[4]

[1]Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA, [2]Center for Brain/Mind medicine, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, [3]Cleveland Clinic, Las Vegas, NV, USA, [4]Discovery Research, Suven Life Sciences, Hyderabad, India

LBP60 - Clinical polysomnography trial of suvorexant for treating insomnia in Alzheimer's disease: trial design and baseline characteristics of participants

W.J. Herring, MD, PhD[1], P. Ceesay, PhD[1], E. Snyder, PhD[1], D. Bliwise, MD[2], K. Budd, BS[1], J. Hutzelmann, BS[1], J. Stevens, BS[1], D. Michelson, MD[1]

[1]Merck & Co. Inc., Kenilworth, NJ, USA, [2]Emory University School of Medicine, Atlanta, GA, USA

LBP61 - Neuroprotective effect of a new photobiomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support a novel hypothesis for therapeutic approach of Alzheimer's disease

Guillaume J. Blivet, MS[1], Laura Auboyer, PhD[1], Johann Meunier, PhD[2], François J. Roman, PhD[2], Jacques Touchon, MD, PhD[3,4]

[1]REGEnLIFE SAS, Montpellier, France, [2]Amylgen SAS, Montferrier-sur-Lez, France, [3]INSERM U1061, Montpellier, France, [4]Neurology Department, University of Montpellier, France

LBP62 - Interest of REGEnLIFE RGn530 photobiomodulation medical device for the treatment of Alzheimer's disease: a double-blind, randomized sham-controlled trial to evaluate the safety and efficacy

Audrey Gabelle, MD, PhD[1,2], Thibault Mura, MD, PhD[2,3], Karim Bennys, MD[1,2], Sophie Navucet, MS[1,2], Martine Flores, MS[1,2], Laura Auboyer, PhD[4], Guillaume J. Blivet, MS[4], Jacques Touchon, MD, PhD[1,2]

[1]Memory Research and Resources Center of Montpellier, Department of Neurology, Montpellier University Hospital, France, [2]MUSE University, Inserm U1061, Montpellier, France, [3]Department of Epidemiologic and Clinical Research, La Colombière Hospital, Montpellier, France, [4]REGEnLIFE SAS, Montpellier, France

Clinical Trials on Alzheimer's Disease

CTAD SPONSORS

CTAD 2018 would like to thank its privileged partners for their continued support of CTAD.

Gold Sponsors

abbvie

Biogen

Eisai

GRIFOLS

Araclon Biotech
GRIFOLS

IMS Health & Quintiles are now
IQVIA

janssen

Lilly

Lundbeck

Pfizer

Roche

CTAD 2018

REGISTRATION

Early bird fees (until September 1)

Early bird registration (no lunches) 995€ - Early bird registration (3 lunches) 1124€

Early bird fees (after September 2)

Full registration (no lunches) 1287€ - Full registration (3 lunches) 1416€

Please note that registration to CTAD 2018 includes:
access to all conference sessions, attendee bag, one-year online subscription
to the *Journal of Prevention of Alzheimer's Disease* (JPAD) and CTAD abstracts

You can register directly on our website www.ctad-alzheimer.com

ACCOMMODATIONS




Book your accommodation close to the Conference Venue

The Fairmont Rey Juan Carlos Hotel connected to the Conference Center is now sold out.

Our housing manager, Christophe Bascoul is dedicated to helping you find the best hotel close to the conference venue.

Contact: CTAD2018hotels@kris-events.com

Phone: +33 6 15 93 22 82

Keep in touch

BARCELONA 2018

CTAD Congress
Phone: + 33 (0)4 67 10 92 23
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Follow us on

@CTADConference

CTAD Alzheimer

CTAD Conference

#CTAD2018

www.ctad-alzheimer.com

CTAD 2019

Alzheimer

Clinical Trials on Alzheimer's Disease

© Istock

December 4-7, 2019
SAN DIEGO, California

Hilton Bayfront San Diego

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14
Barcelona '15 / San Diego '16 / Boston '17 / Barcelona '18

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

EADC

MONTPELLIER and TOULOUSE EADC Centers
European Alzheimer's Disease Consortium

Keck School of Medicine of USC
Alzheimer's Therapeutic Research Institute

JPAD
The Journal of Prevention of Alzheimer's Disease